<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Nat Commun</journal-id><journal-id journal-id-type="iso-abbrev">Nat Commun</journal-id><journal-title-group><journal-title>Nature Communications</journal-title></journal-title-group><issn pub-type="epub">2041-1723</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40393975</article-id><article-id pub-id-type="pmc">PMC12092689</article-id>
<article-id pub-id-type="publisher-id">59408</article-id><article-id pub-id-type="doi">10.1038/s41467-025-59408-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>HIV status alters immune cell infiltration and activation profile in women with breast cancer</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Bauer</surname><given-names>Marcus</given-names></name><address><email>marcus.bauer@uk-halle.de</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3008-014X</contrib-id><name><surname>Santos</surname><given-names>Pablo</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Wilfer</surname><given-names>Andreas</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>van den Berg</surname><given-names>Eunice</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Zietsman</surname><given-names>Annelle</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6642-9585</contrib-id><name><surname>Vetter</surname><given-names>Martina</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Kaufhold</surname><given-names>Sandy</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Wickenhauser</surname><given-names>Claudia</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>dos-Santos-Silva</surname><given-names>Isabel</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3248-4906</contrib-id><name><surname>Chen</surname><given-names>Wenlong Carl</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff8">8</xref><xref ref-type="aff" rid="Aff9">9</xref><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Cubasch</surname><given-names>Herbert</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0009-0009-1980-1805</contrib-id><name><surname>Murugan</surname><given-names>Nivashini</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>McCormack</surname><given-names>Valerie</given-names></name><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Joffe</surname><given-names>Maureen</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff8">8</xref><xref ref-type="aff" rid="Aff13">13</xref><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5544-4958</contrib-id><name><surname>Seliger</surname><given-names>Barbara</given-names></name><address><email>barbara.seliger@uk-halle.de</email></address><xref ref-type="aff" rid="Aff15">15</xref><xref ref-type="aff" rid="Aff16">16</xref><xref ref-type="aff" rid="Aff17">17</xref></contrib><contrib contrib-type="author"><name><surname>Kantelhardt</surname><given-names>Eva</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05gqaka33</institution-id><institution-id institution-id-type="GRID">grid.9018.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 0679 2801</institution-id><institution>Institute of Pathology, University Hospital Halle, </institution><institution>Martin Luther University Halle-Wittenberg, </institution></institution-wrap>Halle (Saale), Germany </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05gqaka33</institution-id><institution-id institution-id-type="GRID">grid.9018.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 0679 2801</institution-id><institution>Global and Planetary Health Working Group, Institute of Medical Epidemiology, Biometrics and Informatics, </institution><institution>Martin Luther University Halle-Wittenberg, </institution></institution-wrap>Halle (Saale), Germany </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04fe46645</institution-id><institution-id institution-id-type="GRID">grid.461820.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 0390 1701</institution-id><institution>Krukenberg Cancer Center, </institution><institution>University Hospital Halle, </institution></institution-wrap>Halle (Saale), Germany </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00znvbk37</institution-id><institution-id institution-id-type="GRID">grid.416657.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 0630 4574</institution-id><institution>Department of Anatomical Pathology, University of the Witwatersrand, </institution><institution>National Health Laboratory Service, </institution></institution-wrap>Johannesburg, South Africa </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.518412.b</institution-id><institution>AB May Cancer Centre, </institution><institution>Windhoek Central Hospital, </institution></institution-wrap>Windhoek, Namibia </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05gqaka33</institution-id><institution-id institution-id-type="GRID">grid.9018.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 0679 2801</institution-id><institution>Department of Gynecology, University Hospital Halle, </institution><institution>Martin Luther University Halle-Wittenberg, </institution></institution-wrap>Halle (Saale), Germany </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00a0jsq62</institution-id><institution-id institution-id-type="GRID">grid.8991.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 0425 469X</institution-id><institution>Department of Non-Communicable Disease Epidemiology, </institution><institution>London School of Hygiene and Tropical Medicine (LSHTM), </institution></institution-wrap>London, UK </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03rp50x72</institution-id><institution-id institution-id-type="GRID">grid.11951.3d</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 1135</institution-id><institution>Strengthening Oncology Services Research Unit, Faculty of Health Sciences, </institution><institution>University of the Witwatersrand, </institution></institution-wrap>Johannesburg, South Africa </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03rp50x72</institution-id><institution-id institution-id-type="GRID">grid.11951.3d</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 1135</institution-id><institution>Sydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, </institution><institution>University of the Witwatersrand, </institution></institution-wrap>Johannesburg, South Africa </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00znvbk37</institution-id><institution-id institution-id-type="GRID">grid.416657.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 0630 4574</institution-id><institution>National Cancer Registry, </institution><institution>National Health Laboratory Service, </institution></institution-wrap>Johannesburg, South Africa </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03rp50x72</institution-id><institution-id institution-id-type="GRID">grid.11951.3d</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 1135</institution-id><institution>Department of Surgery, School of Clinical Medicine, Faculty of Health Sciences, </institution><institution>University of the Witwatersrand, </institution></institution-wrap>Johannesburg, South Africa </aff><aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00v452281</institution-id><institution-id institution-id-type="GRID">grid.17703.32</institution-id><institution-id institution-id-type="ISNI">0000 0004 0598 0095</institution-id><institution>International Agency for Research on Cancer (IARC/WHO), </institution><institution>Environment and Lifestyle Epidemiology Branch, </institution></institution-wrap>Lyon, France </aff><aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03rp50x72</institution-id><institution-id institution-id-type="GRID">grid.11951.3d</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 1135</institution-id><institution>Noncommunicable Diseases Research Division, Wits Health Consortium (PTY) Ltd, </institution><institution>University Witwatersrand, </institution></institution-wrap>Johannesburg, South Africa </aff><aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03rp50x72</institution-id><institution-id institution-id-type="GRID">grid.11951.3d</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 1135</institution-id><institution>Strengthening Oncology Services Research Unit,Faculty of Health Sciences, </institution><institution>University Witwatersrand, </institution></institution-wrap>Johannesburg, South Africa </aff><aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05gqaka33</institution-id><institution-id institution-id-type="GRID">grid.9018.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 0679 2801</institution-id><institution>Medical Faculty, </institution><institution>Martin Luther University Halle-Wittenberg, </institution></institution-wrap>Halle (Saale), Germany </aff><aff id="Aff16"><label>16</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04x45f476</institution-id><institution-id institution-id-type="GRID">grid.418008.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 0494 3022</institution-id><institution>Fraunhofer Institute for Cell Therapy and Immunology, </institution></institution-wrap>Leipzig, Germany </aff><aff id="Aff17"><label>17</label>Institute of Translational Immunology, Medical School Theodor Fontane, Brandenburg an der Havel, Germany </aff></contrib-group><pub-date pub-type="epub"><day>20</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>20</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>16</volume><elocation-id>4699</elocation-id><history><date date-type="received"><day>21</day><month>5</month><year>2024</year></date><date date-type="accepted"><day>23</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">The breast cancer (BC)-related mortality is higher and the immunity is altered in women living with HIV (WLWH) compared to HIV-negative women. Therefore, tumor samples of 296 black BC patients from South Africa and Namibia with known age, HIV status, tumor stage, hormone receptor and HER2 status and overall survival (OS) are analyzed for components of the tumor microenvironment (TME). WLWH (<italic>n</italic>&#x02009;=&#x02009;117), either with suppressed viral activity (HR&#x02009;=&#x02009;1.25) or with immune suppression (HR&#x02009;=&#x02009;2.04), have a shorter OS. HIV status is associated with increased numbers of CD8<sup>+</sup> T cells in the TME compared to HIV-negative patients; no correlation is found with CD4<sup>+</sup> T cell numbers in the blood. Moreover, an increased expression of CD276/B7-H3 and a more pronounced IFN-&#x003b3; signaling in the tumors are found in WLWH, independent of age, stage, and BC subtypes. In conclusion, altered T cell composition and CD276 expression in WLWH may contribute to inferior survival and can be used for targeted treatment.</p></abstract><abstract id="Abs2" abstract-type="web-summary"><p id="Par2">Cancer is subject to immune surveillance, and HIV infection dampens immune capacity, but HIV-induced immune alterations in patients with breast cancer is still unclear. Here the authors profile women living with HIV to find increased CD8 T cell tumor infiltration, enhanced checkpoint molecular expression, and reduced overall survival when compared with controls.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Breast cancer</kwd><kwd>Tumour immunology</kwd><kwd>Virus-host interactions</kwd><kwd>Epidemiology</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Nature Limited 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par3">Female breast cancer (BC) is the most common type of cancer worldwide and an increasing public health concern in sub&#x02010;Saharan Africa (SSA)<sup><xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref></sup>. Due to a weaker health infrastructure with predominantly diagnosis at an advanced stage and limited treatment options, the survival of BC patients in SSA is particularly low when compared to patients in Europe or North America<sup><xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR6">6</xref></sup>. In addition to this, differences in the BC biology including a distinct regional variation in the distribution of BC subtypes, genetic aberrations and the tumor microenvironment (TME) have been reported with unfavorable prognostic factors in Western Africa<sup><xref ref-type="bibr" rid="CR7">7</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref></sup>. In Southern and Eastern Africa, an additional factor influencing BC management and survival is the relatively high population prevalence of human immunodeficiency virus (HIV)<sup><xref ref-type="bibr" rid="CR10">10</xref></sup> that influences the tumor biology and patients&#x02019; tolerability and response to therapy and survival outcomes.</p><p id="Par4">There are large age- and sex-specific as well as a regional variations in HIV prevalence across SSA<sup><xref ref-type="bibr" rid="CR11">11</xref></sup> with Namibia, South Africa, Lesotho and Botswana exhibiting the highest prevalence<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>. The development of highly active anti-retroviral therapy (HAART) was a major breakthrough and has dramatically improved patients&#x02019; survival<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>. In recent years, the availability of HAART was accompanied by a substantially reduced AIDS related mortality<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>. Consequently, women living with HIV (WLWH) live to ages when BC incidence rates in the population are rising. Thus, WLWH and BC represent a substantial proportion of the BC patient profile in these Southern African countries<sup><xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR16">16</xref></sup>.</p><p id="Par5">Recently, comparison of WLWH with BC and HIV negative BC patients demonstrated a younger age at diagnosis and poorer overall survival of WLWH (HR&#x02009;=&#x02009;1.49). The inferior survival in WLWH was independent of age, stage and the hormone receptor status<sup><xref ref-type="bibr" rid="CR15">15</xref>&#x02013;<xref ref-type="bibr" rid="CR17">17</xref></sup>, but a higher prevalence of TNBC was reported recently<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. Of note, both WLWH with &#x0003c;50 viral load copies/mL and WLWH with &#x02265;50 viral load copies/mL had a poorer survival than HIV negative BC patients<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. In addition, a small study reported that 17 people living with HIV who developed a malignancy in the course of the HIV disease showed an increased T cell dysfunction and exhaustion prior to cancer diagnosis<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>. This was accompanied by an increased expression of immune checkpoint (ICP) molecules, such as the programmed death receptor 1 (PD-1) as a major regulatory factor upon HIV infection<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. These data suggest a complex HIV associated immune deregulation even upon HAART. However, the influence of the HIV infection on the composition of the TME and the expression of immune-relevant molecules on tumors has not yet been analyzed in detail.</p><p id="Par6">Therefore, the objectives of this study are to compare the immune cell composition and functionality as well as the expression of immune modulatory molecules between WLWH and HIV negative BC patients, overall and stratified by age, stage, and hormone receptor status, which might give further insights into the lower survival rate of WLWH with BC. A better understanding regarding the function of the cellular and non-cellular components of the TME contributing to tumorigenesis and disease progression of BC in WLWH will have an impact on the intervention and treatment of those patients.</p></sec><sec id="Sec2" sec-type="results"><title>Results</title><sec id="Sec3"><title>Association of the HIV status with the clinical stage, IHC groups, and BC patients&#x02019; OS</title><p id="Par7">In order to analyze the influence of HIV status on BC biology we compared clinical and biological variables in relation to HIV status (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>) (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Of the 117 WLWH, 10% were Namibian, whereas of the 179 HIV negative BC patients, 37% were Namibian. This strong HIV-country association of HIV status implies that crude differences between HIV positive and HIV negative patients may be due to differences between the countries and not due to HIV infection, unless country-specific models are presented or unless there is an adjustment for the country.<fig id="Fig1"><label>Fig. 1</label><caption><title>Graphical abstract.</title><p>Tumor samples of 296 black women with breast cancer (BC) from South Africa and Namibia and known age at diagnosis, HIV status, clinical tumor stage, BC hormone receptor and HER2 status as well as overall survival (OS) were analyzed for components of the BC tumor microenvironment (TME). The frequency of tumor infiltrating lymphocytes (TILs), immune cell subpopulations and the expression profile of immune modulatory molecules were analyzed by histomorphology, RNA expression analysis and multiplex immunohistochemistry (MSI). Women living with HIV (WLWH) (<italic>n</italic>&#x02009;=&#x02009;117) had a shorter OS, both WLWH with suppressed viral activity (HR&#x02009;=&#x02009;1.25) and with immune suppression (HR&#x02009;=&#x02009;2.04). HIV status was associated with increased numbers of CD8<sup>+</sup> T cells in the TME compared to HIV negative BC patients, which did not correlate with CD4<sup>+</sup> T cell numbers in the blood. Moreover, an increased protein expression of immune checkpoint molecule CD276/B7-H3 and a more pronounced IFN-&#x003b3; signaling in the tumors were found in WLWH, independent of age, stage, and BC subtypes. The graphical abstract was created in BioRender (Bauer, M. (2025) <ext-link ext-link-type="uri" xlink:href="https://BioRender.com/aaf1liv">https://BioRender.com/aaf1liv</ext-link>).</p></caption><graphic xlink:href="41467_2025_59408_Fig1_HTML" id="d33e559"/></fig><table-wrap id="Tab1"><label>Table 1</label><caption><p>Clinical and immunological parameters in breast cancer specimens and patients (<italic>n</italic>&#x02009;=&#x02009;296)</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Parameters</th><th/><th>WLWH - VS</th><th>WLWH - IS</th><th>HIV negative</th></tr></thead><tbody><tr><td colspan="2">Number of patients</td><td>70</td><td>47</td><td>179</td></tr><tr><td>Country of origin</td><td><p>South Africa (n)</p><p>Namibia (n)</p></td><td><p>58</p><p>12</p></td><td><p>47</p><p>0</p></td><td><p>113</p><p>66</p></td></tr><tr><td colspan="2">Age (mean)</td><td>27-81 (48)</td><td>30-81 (49)</td><td>29-98 (57)</td></tr><tr><td><p>Stage</p><p>(simplified)</p></td><td><p>Early</p><p>Advanced</p></td><td><p>24 (34.3%)</p><p>46 (65.7%)</p></td><td><p>5 (10.6%)</p><p>42 (88.4%)</p></td><td><p>62 (34.6%)</p><p>117 (65.4%)</p></td></tr><tr><td><p>Stage</p><p>(UICC)</p></td><td><p>I</p><p>II</p><p>III</p><p>IV</p></td><td><p>3 (4.2%)</p><p>45 (64.3%)</p><p>18 (25.7%)</p><p>4 (5.8%)</p></td><td><p>0 (0%)</p><p>24 (51.1%)</p><p>19 (40.4%)</p><p>4 (8.5%)</p></td><td><p>7 (3.9%)</p><p>88 (49.2%)</p><p>63 (35.2%)</p><p>21 (11.7%)</p></td></tr><tr><td>Grading</td><td><p>G1</p><p>G2</p><p>G3</p></td><td><p>2 (2.9%)</p><p>35 (50.0%)</p><p>33 (47.1%)</p></td><td><p>2 (4.3%)</p><p>25 (53.2%)</p><p>20 (42.6%)</p></td><td><p>15 (8.5%)</p><p>90 (51.1%)</p><p>71 (40.4%)</p></td></tr><tr><td>Ki67 index</td><td><p>&#x0003c;25%</p><p>&#x02265;25%</p></td><td><p>24 (34.3%)</p><p>46 (65.7%)</p></td><td><p>10 (21.3%)</p><p>37 (88.7%)</p></td><td><p>76 (43.2%)</p><p>100 (56.8%)</p></td></tr><tr><td>IHC groups</td><td><p>Luminal A-like</p><p>Luminal B-like</p><p>HER2+</p><p>TNBC</p></td><td><p>18 (25.7%)</p><p>36 (51.4%)</p><p>7 (10.0%)</p><p>9 (12.9%)</p></td><td><p>4 (8.5%)</p><p>29 (61.7%)</p><p>6 (12.8%)</p><p>8 (17.0%)</p></td><td><p>62 (34.7%)</p><p>72 (40.2%)</p><p>16 (8.9%)</p><p>29 (16.2%)</p></td></tr><tr><td>TILs</td><td><p>&#x0003c;10%</p><p>10-39%</p><p>&#x02265;40%</p></td><td><p>27 (38.6%)</p><p>32 (45.7%)</p><p>11 (15.7%)</p></td><td><p>22 (46.8%)</p><p>22 (46.8%)</p><p>3 (6.4%)</p></td><td><p>85 (48.3%)</p><p>70 (39.8%)</p><p>21 (11.9%)</p></td></tr><tr><td><p>T cell</p><p>Infiltration</p></td><td><p>CD3<sup>+</sup>(mean)</p><p>CD3<sup>+</sup>CD8<sup>-</sup>(mean)</p><p>CD3<sup>+</sup>CD8<sup>+</sup>(mean)</p><p>CD3<sup>+</sup>FoxP3<sup>+</sup>(mean)</p></td><td><p>8.2%</p><p>2.3%</p><p>4.7%</p><p>1.2%</p></td><td><p>7.5%</p><p>1.2%</p><p>5.6%</p><p>0.7%</p></td><td><p>3.6%</p><p>1.1%</p><p>1.9%</p><p>0.6%</p></td></tr><tr><td><p>T cell</p><p>proximity</p><p>(&#x000b5;m)</p></td><td><p>CD3<sup>+</sup>T cell&#x02192;CD8<sup>+</sup> T cell (mean)</p><p>CD3+T cell&#x02192;Treg (mean)</p><p>CD8+T cell&#x02192;Treg (mean)</p><p>CD3+T cell&#x02192; panCK<sup>+</sup> cancer cell (mean)</p></td><td><p>24&#x02009;&#x000b5;m</p><p>72&#x02009;&#x000b5;m</p><p>59&#x02009;&#x000b5;m</p><p>31&#x02009;&#x000b5;m</p></td><td><p>27&#x02009;&#x000b5;m</p><p>88&#x02009;&#x000b5;m</p><p>86&#x02009;&#x000b5;m</p><p>30&#x02009;&#x000b5;m</p></td><td><p>56&#x02009;&#x000b5;m</p><p>105&#x02009;&#x000b5;m</p><p>32&#x02009;&#x000b5;m</p><p>29&#x02009;&#x000b5;m</p></td></tr></tbody></table><table-wrap-foot><p><italic>BC</italic> breast cancer, <italic>HER2</italic>&#x02009;+&#x02009; human epidermal growth factor receptor 2 positive, <italic>IHC</italic> immunohistochemistry, <italic>TILs</italic> tumor infiltrating lymphocytes, <italic>TNBC</italic> triple negative breast cancer, <italic>WLWH - IS</italic> women living with <italic>HIV</italic> &#x02013; immune suppressed, <italic>WLWH - VS</italic> women living with <italic>HIV</italic> &#x02013; viral suppressed.</p></table-wrap-foot></table-wrap></p><p id="Par8">From those 117 WLWH with BC, 47 patients showed low CD4<sup>+</sup> T cell counts (&#x0003c;500&#x02009;cell/mm<sup>3</sup>) and detectable viral loads in the blood at the time point of diagnosis. Those individuals were categorized as WLWH immune suppressed (WLWH - IS), while WLWH with higher counts of CD4<sup>+</sup> T cells and no detectable viral loads were classified as WLWH virally suppressed (WLWH - VS). Principal component analysis (PCA) showed an overlap in features of BC specimens from WLWH - IS and WLWH - VS, while the samples of HIV negative BC patients were partially separated (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2A</xref>). Comparison of clinical variables revealed a younger mean age in WLWH with BC at time of diagnosis (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2B</xref>, Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) as expected. Moreover, no differences regarding proportions of TNBC and HER2&#x02009;+&#x02009;BC were found between WLWH and HIV negative BC patients (see Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> and Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2C, D</xref>). Next, we analyzed OS in 291 patients. Univariate analysis (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2E</xref>) revealed a higher risk in patients with higher numbers of children (HR&#x02009;=&#x02009;1.08, 95% CI:1.00&#x02013;1.18), younger age (HR&#x02009;=&#x02009;1.12, 95% CI: 1.01&#x02013;-1.21), advanced clinical stage (HR&#x02009;=&#x02009;3.24, 95% CI: 2.11&#x02013;4.98), HER2&#x02009;+&#x02009;BC and TNBC (HR&#x02009;=&#x02009;2.01, 95% CI: 1.11&#x02013;3.65 and HR&#x02009;=&#x02009;1.77, 95% CI: 1.13&#x02013;2.79, respectively). WLWH - IS showed worse outcome (HR&#x02009;=&#x02009;2.04, 95% CI: 1.17&#x02013;3.56) compared to WLWH - VS. Patients, who received endocrine treatment or radiation therapy showed better survival.<fig id="Fig2"><label>Fig. 2</label><caption><title>Breast cancer biology and overall survival in sub-Saharan Africa.</title><p><bold>A</bold> PCA of BC samples and clinical features from HIV negative and WLWH BC patients. <bold>B</bold> Association of age with HIV status. <bold>C</bold>, <bold>D</bold> Distribution of IHC groups with regard to HIV status and country of origin. <bold>E</bold> Univariate Cox regression of 296 BC patients regarding their risk of death. The number of patients in each reference group, the hazard ratio and the 95% confidence interval, as well as the p-value are given. <bold>F</bold> Representative H&#x00026;E staining of FFPE BC samples with low, intermediate and high (from left to right) infiltration, scale bars depict 50&#x02009;&#x000b5;m. TIL scoring was performed by two pathologists independently. <bold>G</bold> Box plots show the distribution of TIL numbers in different IHC groups and regarding HIV status. The mean is given as a dashed line and the standard deviation is given as a dot line. Categories were compared using the Mann&#x02013;Whitney U test and p-values are given as numbers if <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05. <bold>H</bold> Multivariate Cox regression of 296 BC patients regarding their risk of death. The number of patients in each reference group, the hazard ratio and the 95% confidence interval, as well as the p-value are given. Abbreviations: BC breast cancer, HER2&#x02009;+&#x02009; human epidermal growth factor receptor 2 positive, PCA principal component analysis, TILs tumor infiltrating lymphocytes, SA South Africa, WLWH - IS women living with HIV &#x02013; immune suppressed, WLWH - VS women living with HIV &#x02013; viral suppressed.</p></caption><graphic xlink:href="41467_2025_59408_Fig2_HTML" id="d33e903"/></fig></p></sec><sec id="Sec4"><title>Frequency of TILs is associated with the HIV status</title><p id="Par9">The frequency of TILs in the TME had no significant prognostic value (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2E</xref>) in the studied BC patient cohort (representative H&#x00026;E staining images in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2F</xref>). A mean higher TIL frequency was found in HER2+ and TNBC compared to the Luminal A-like BC (<italic>p</italic>&#x02009;=&#x02009;0.002). Moreover, a higher TIL density was found in WLWH - VS compared to HIV negative patients (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2G</xref>), while we found no statistically significant difference between WLWH &#x02013; IS and WLWH &#x02013; VS or WLWH &#x02013; IS and HIV negative BC patients. In order to understand the prognostic value of tumor intrinsic factors, HIV status and abundancy of TILs, a multivariate Cox regression analysis including country of origin, number of children, clinical stage, IHC groups, HIV status, treatment, and the density of TILs was performed. As shown in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2H</xref>, the hazard ratio for WLWH - VS was reduced from 1.25 in the univariate analysis to 0.95 in the multivariate analysis, while it decreased in WLWH - IS BC patients from 2.04 to 1.34. Adjustment for IHC groups was the factor attenuating the HIV effect on patients&#x02019; outcome. Higher frequencies of TILs showed no statistically significant prognostic value after adjustment.</p></sec><sec id="Sec5"><title>Aberrant T cell infiltration in the BC TME of WLWH</title><p id="Par10">Despite only differences in the TIL density were found in tumors of WLWH - VS versus HIV negative BC patients, the composition of the immune cell subpopulations as well as the expression of different immune relevant molecules, like ICPs and HLA class I antigens, was determined. First, the bulk RNA expression of the whole tumor including its TME (<italic>n</italic>&#x02009;=&#x02009;296) was analyzed for the expression profile of 41 different immune genes (Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">1</xref>) employing an unsupervised clustering model as shown in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>. The clusters based on the expression of the 41 different genes did neither associate with the HIV status, nor with other parameters, such as the clinical stage, tumor grading, tumor cell proliferation Ki67 index, and the IHC groups.<fig id="Fig3"><label>Fig. 3</label><caption><title>Immune gene expression in breast cancer specimens.</title><p>Unsupervised clustering of the RNA expression of 41 genes used for the TME classification of 296 BC samples with known HIV status of patients&#x02019; is given as a heatmap. Red tiles denote increased expression, while blue tiles correspond to decreased expression. The six horizontal bars above the heatmap indicate the classification of samples according to country, stage, Ki67, TILs, IHC groups and HIV status. Color codes for each bar and relative expression are given at the right side of the figure. Abbreviations: BC breast cancer, HER2&#x02009;+&#x02009; human epidermal growth factor receptor 2 positive, IHC immunohistochemistry, TILs tumor infiltrating lymphocytes, TNBC triple negative breast cancer, WLWH - IS women living with HIV &#x02013; immune suppressed, WLWH - VS women living with HIV &#x02013; viral suppressed.</p></caption><graphic xlink:href="41467_2025_59408_Fig3_HTML" id="d33e943"/></fig></p><p id="Par11">However, univariate explanatory analysis of all immune genes indicated candidate genes, namely CD4, CD8, and CD276, to be associated with the HIV status. In order to investigate the impact of the HIV status on the expression of these genes in the BC TME, we next analyzed the interrelationship of HIV status on the expression of CD4, CD8, and CD276 (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4A&#x02013;F</xref>) demonstrating a lower CD4 expression in WLWH - VS, but a trend of higher CD8 expression in WLWH - IS. In WLWH - IS, a trend of higher CD276 expression was also detected. Multivariate analysis including socio-economic factors and treatment are shown for all three markers in the Supplementary Figs.&#x000a0;<xref rid="MOESM1" ref-type="media">1</xref>&#x02013;<xref rid="MOESM1" ref-type="media">3</xref>. Next, Pearson correlation of different TME factors revealed a correlation of CD276 RNA expression with CD4, CD56 and CD68, while Tregs (FOXP3), B cells (CD20) and granzyme B (grB) showed an inverse correlation (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4G</xref>). In addition, the same analysis was performed separated by the HIV status (Supplementary Figs.&#x000a0;<xref rid="MOESM1" ref-type="media">4</xref>&#x02013;<xref rid="MOESM1" ref-type="media">5</xref>). Moreover, an independent prognostic value for CD4 and CD276 RNA expression was found in a multivariate Cox regression (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4H</xref>). Higher CD4 expression was associated with improved patients&#x02019; outcomes (HR&#x02009;=&#x02009;0.607, 95% CI: 0.41&#x02013;0.89), while higher CD276 expression was linked with worse outcomes (HR&#x02009;=&#x02009;1.596, 95% CI: 1.01&#x02013;2.55).<fig id="Fig4"><label>Fig. 4</label><caption><title>Distinct RNA expression profile of immune-relevant genes in breast cancer samples of WLWH and HIV negative patients.</title><p><bold>A</bold>&#x02013;<bold>F</bold> Association between HIV status and CD4, CD8 and CD276 RNA expression in WLWH &#x02013; VS and WLWH&#x02013;IS versus HIV negative BC patients, in a multivariate analysis. <bold>G</bold> Correlation map of selected immune genes of all patients, irrespective of HIV status. The correlation values are shown in different colors with red tiles denote a positive correlation, while blue tiles correspond to a negative correlation. <bold>H</bold> Multivariate Cox&#x02019;s regression with stage, IHC groups, HIV status, CD4, CD8, and CD276 expression of 296 patients regarding their risk of death. The number of patients in each reference group, the hazard ratio and the 95% confidence interval, as well as the p-value are given. Abbreviations: FC fold change, WLWH &#x02013; IS women living with HIV &#x02013; immune suppressed, WLWH &#x02013; VS women living with HIV &#x02013; viral suppressed.</p></caption><graphic xlink:href="41467_2025_59408_Fig4_HTML" id="d33e987"/></fig></p><p id="Par12">Association of an increased CD276 expression, interferon gamma (IFN-&#x003b3;) signaling and T cell exhaustion is associated with an aberrant spatial T cell distribution in the BC TME of WLWH</p><p id="Par13">Since a prognostic impact for CD276 was found and the CD4 and CD8 gene expression were associated with HIV status, 48 BC specimens, containing 24 cases of WLWH (8 WLWH&#x02013;VS, 16 WLWH&#x02013;IS) and 24 cases of HIV negative patients were subjected to MSI using two 8-plex panels including CD3, CD8, FoxP3, IDO-1, PD-1, LAG-3, CTLA4, and CD69, as well as panCK, CD3, pStat1, ISG15, HLA-I heavy chain (HC), HLA-G, TAP1, and CXCR4. First, the different T cell populations (CD3<sup>+</sup>CD8<sup>-</sup> T cells, CD3<sup>+</sup>CD8<sup>+</sup> T cells and CD3<sup>+</sup>FoxP3<sup>+</sup> regulatory T cells (Tregs)) were analyzed as representatively shown in Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5A</xref>. While the percentage of CD3<sup>+</sup>CD8<sup>-</sup> T cells (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5B</xref>) was comparable in WLWH and HIV negative patients, CD3<sup>+</sup>CD8<sup>+</sup> T cell numbers were higher in WLWH overall, but particularly WLWH - IS (p&#x02009;=&#x02009;0.033, Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5C</xref>). The frequency of CD3<sup>+</sup>FoxP3<sup>+</sup> Treg was higher in WLWH - VS (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5D</xref>). Pearson correlation analysis revealed no association of the frequency of TILs, CD3<sup>+</sup>CD8<sup>-</sup> / CD3<sup>+</sup>CD8<sup>+</sup> T cells or CD3<sup>+</sup>FoxP3<sup>+</sup> Tregs and the number of CD4<sup>+</sup> T cells in the peripheral blood in WLWH as well as in T subpopulations like CD3<sup>+</sup>CD8<sup>-</sup> and CD3<sup>+</sup>CD8<sup>+</sup> T cells (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5E&#x02013;H</xref>). The spatial proximity of CD3<sup>+</sup>CD8<sup>-</sup> and CD3<sup>+</sup>CD8<sup>+</sup> T cell subsets was increased in the TME of WLWH. Moreover, WLWH - VS showed a closer spatial proximity of CD3<sup>+</sup>CD8<sup>-</sup> and CD3<sup>+</sup>CD8<sup>+</sup> T cells to CD3<sup>+</sup>FoxP3<sup>+</sup> Tregs (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5I</xref>). Next, the expression of CD276 was analyzed by IHC as representatively shown in Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5J</xref> and revealed a higher CD276 protein expression in WLWH - IS (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5K</xref>). The interrelationship of TIL density, CD276 expression and the numbers of different T cell subpopulations is shown in Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5L</xref>. CD276 expression was not associated with CD4<sup>+</sup> T cell numbers in the peripheral blood and TIL density, but correlated with higher numbers of CD3<sup>+</sup>CD8<sup>+</sup> T cells in the BC TME (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5M&#x02013;O</xref>). Interestingly, a spatial heterogeneity of CD276 expression was found within the tumors that was associated with regional differences of TIL densities (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>). In addition, the expression of different immune response relevant molecules was analyzed as representatively shown in Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7A</xref> (for all antigens refer to Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">6</xref>). The expression of both, CTLA4 and LAG3 was increased in different T cell subsets, while the PD-1 expression was only slightly higher in WLWH (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7B&#x02013;D</xref>) and no difference was found in the CD69 surface expression (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">7A</xref>). However, a higher expression of IFN-&#x003b3; signaling pathway component ISG15 and a trend to higher pSTAT1 were found in WLWH - VS (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7E, F</xref>). ISG15 expression was not associated with CD4<sup>+</sup> T cell numbers in the blood, but was linked with higher CD276 expression (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">7B, C</xref>). The expression of HLA-I HC and HLA-G did not significantly differ between the respective groups (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7G, H</xref>). Higher expression of HLA-I HC was associated with a trend of higher CD3<sup>+</sup>CD8<sup>+</sup> T cells in the TME and lower CD4<sup>+</sup> T cell numbers in the peripheral blood (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">7D, E</xref>). The protein expression of TAP1, IDO-1, and CXCR4 showed no differences (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7I</xref>, Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">7F, G</xref>). To validate the higher expression of IFN-&#x003b3; signaling pathway components, the publicly available RNA expression data set GSE149156<sup><xref ref-type="bibr" rid="CR21">21</xref></sup> was employed. Analysis of bulk RNAseq data from 6 BC specimens of WLWH versus samples from 3 HIV negative BC patients demonstrated 230 significantly downregulated and 285 significantly upregulated genes (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7J</xref>). By focussing on immune-related genes (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7K</xref>, genes summarized in Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">2</xref>), an upregulation of CD14, IFNAR2 and CD55 could be demonstrated, while OAS1 and CD8B showed no significant upregulation. To get insights in the expression of different biologically relevant gene sets a GSEA was performed employing the MSigDB_Hallmark_2020 gene set. This revealed 24 significantly upregulated gene sets in BC specimens of WLWH including the inflammatory response, TNF- &#x003b1; signaling via NF-kB, TGF-&#x003b2; signaling, IFN-&#x003b1; and IFN-&#x003b3; response, while only the myc target V1 gene set was downregulated (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7L</xref> and Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">8</xref>).<fig id="Fig5"><label>Fig. 5</label><caption><title>Distinct immune cell composition in the tumor microenvironment of HIV positive and HIV negative breast cancer patients.</title><p><bold>A</bold> Multiplex IHC using an Ab panel directed against CD3 (yellow), CD8 (magenta), FoxP3 (turquoise) and counterstained with DAPI (blue). The scale bar depicts 50&#x02009;&#x000b5;m. For the analysis from each sample three areas were selected and cell counts and marker expression was extracted. <bold>B</bold>&#x02013;<bold>D</bold> The amount of T cell subsets in the BC TME of HIV negative patients and WLWH. The mean is given as a dashed line and the standard deviation is given as a dot line. Categories were compared using the Mann&#x02013;Whitney U test and p-values are given as numbers if <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05. <bold>E</bold>&#x02013;<bold>H</bold> Scatter plot, overlaid with the corresponding linear regression model and associated <italic>p</italic> value (two-sided) is shown for the correlation of different immune cell subsets in the TME and the numbers of CD4&#x02009;+&#x02009;T cells in the peripheral blood. <bold>I</bold> The spatial distribution (mean distance of CD3&#x02009;+&#x02009;T cells and CD8&#x02009;+&#x02009;T cells; FoxP3+ Tregs and CD3&#x02009;+&#x02009;T cells, FoxP3+ Tregs and CD8&#x02009;+&#x02009;T cells as well as CD3&#x02009;+&#x02009;T cells and panCK+ cancer cells) was analyzed and is shown with box plots. The mean is given as a dashed line and the standard deviation is given as a dot line. <bold>J</bold> Representative picture of a CD276 immunohistochemistry with a strong stained and a negative case. <bold>K</bold> CD276 was analyzed by two pathologists independently using an H score and the expression in WLWH and HIV negative patients is shown in box plots. The mean is given as a dashed line and the standard deviation is given as a dot line. <bold>L</bold> Bar graph shows the percentage of CD3&#x02009;+&#x02009;CD8- (blue), CD3&#x02009;+&#x02009;CD8+ (red), CD3+FoxP3+ (yellow), and all other cells (gray, e.g., stroma, tumor cells) separated by HIV status and is association with TIL numbers in the stroma evaluated on the H&#x00026;E stained, as well as the CD276/B7-H3 expression analyzed by IHC. <bold>M</bold>&#x02013;<bold>O</bold> Association of CD276 expression and CD4&#x02009;+&#x02009;T cell numbers in the peripheral blood, TILs in the TME, and CD3&#x02009;+&#x02009;CD8+ is shown with a scatter plot, overlaid with the corresponding linear regression model and associated p-values (two-sided) are given. Abbreviations: TILs tumor infiltrating lymphocyte, WLWH - IS women living with HIV &#x02013; immune suppressed, WLWH - VS women living with HIV&#x02013;viral suppressed.</p></caption><graphic xlink:href="41467_2025_59408_Fig5_HTML" id="d33e1213"/></fig><fig id="Fig6"><label>Fig. 6</label><caption><title>CD276 protein expression in the BC TME.</title><p>Example of a CD276 staining of a BC sample of a HIV positive patient showing a spatial heterogeneity with a high expression in region 1 in comparison to region 2 with a lower CD276 expression. Tumor cells are marked with asterisks and TILs are highlighted with arrows. The scale bar depicts 500&#x02009;&#x000b5;m.</p></caption><graphic xlink:href="41467_2025_59408_Fig6_HTML" id="d33e1221"/></fig><fig id="Fig7"><label>Fig. 7</label><caption><title>ICP expression and IFN-&#x003b3; signaling in BC.</title><p><bold>A</bold> Representative pictures of panCK+ cancer cells (gray), HLA-I HC (yellow), pStat1 (red), CTLA4 (orange), and LAG3 (green). The scale bar depicts 50&#x02009;&#x000b5;m. <bold>B</bold>&#x02013;<bold>D</bold> The expression of ICP molecules CTLA4, PD-1 and LAG3 were tested on different T cell subpopulations. The mean is given as a dashed line and the standard deviation is given as a dot line. Categories were compared using the Mann&#x02013;Whitney U test and p-values are given as numbers if <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05. <bold>E</bold>&#x02013;<bold>I</bold> The expression of pStat1, ISG15, HLA-I HC, HLA-G and TAP1. The mean is given as a dashed line and the standard deviation is given as a dot line. Categories were compared using the Mann&#x02013;Whitney U test and p-values are given as numbers if <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05. <bold>J</bold> Volcano plot depiction of differentially expressed genes in WLWH versus HIV negative BC (GSE149156) for all genes and <bold>K</bold> immune related genes. Significantly upregulated genes are marked in red, significantly downregulated genes in blue. <bold>L</bold> Bar plot depiction of GSEA (MSigDB_Hallmark_2020) of WLWH versus HIV negative. The NES is given as the value of the bars and the FDR is depicted in different colors. Gene sets with a significant up-/down-regulation are highlighted with bold letters. Abbreviations: CXCR4 CXC motif chemokine receptor 4, CTLA4 cytotoxic T-lymphocyte-associated protein 4, GSEA gene set enrichment analysis, HLA human leucocyte antigen, ISG15 Interferon-stimulated gene 15, LAG3 lymphocyte-activation gene 3, panCK pan-cytokeratin, PD-1 programmed cell death protein 1, TAP transporter of antigen processing, WLWH women living with HIV.</p></caption><graphic xlink:href="41467_2025_59408_Fig7_HTML" id="d33e1260"/></fig></p></sec></sec><sec id="Sec6" sec-type="discussion"><title>Discussion</title><p id="Par14">Despite the incidence of AIDS related malignancies like Kaposi sarcoma or non-Hodgkin lymphoma decreased in the era of HAART people living with HIV still have an increased cancer risk<sup><xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR22">22</xref></sup>. In addition, those patients also show a reduced overall survival when compared with HIV negative cancer patients<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>. Thus, a better understanding of the underlying causes of this difference is urgently needed in order to develop strategies for reducing mortality among this patient group. During the last years, not only tumor intrinsic factors, but also the TME, the patients&#x02019; immunity, environmental factors and (viral) infections have been shown to influence the initiation and progression of malignant diseases<sup><xref ref-type="bibr" rid="CR23">23</xref>&#x02013;<xref ref-type="bibr" rid="CR26">26</xref></sup>. Therefore, this study addressed the possible association between the BC biology, immune cell composition and expression of immune relevant markers, like ICP molecules, HLA antigens, APM components and IFN-&#x003b3; signaling pathway components in the TME and its interrelationship with chronic HIV infection.</p><p id="Par15">For this purpose, samples from two different study cohorts of BC patients from South Africa and Namibia with known clinical course were used. As already reported, we found a younger age at diagnosis in WLWH with BC, while no differences among the proportions of HR and HER2 expression status could be detected<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. Histopathological analysis of the TME by determining the TIL densities in the BC stroma revealed that this well-established biomarker<sup><xref ref-type="bibr" rid="CR27">27</xref></sup> showed no predictive relevance in this patient cohort and that WLWH &#x02013; VS showed the highest mean TIL abundancy. Therefore, an exploratory analysis of the gene expression of 41 immune genes was carried out and revealed an upregulation of CD8 and CD276, but a downregulation of CD4 in the TME of WLWH. Of note, higher CD8 expression in BC samples from WLWH has been previously associated with improved outcome in BC<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>, but high numbers of exhausted T cells predicted shorter survival in some BC subtypes<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>. Since the HIV infection preceded BC in WLWH, the influence of HIV status on the expression of the immune genes was analyzed demonstrating differences in the CD4, CD8, and CD276 RNA expression between BC samples from HIV negative individuals versus WLWH with viral suppression and/or immune suppression. Considering there exists not always a coordinated mRNA and protein expression, the expression of immune relevant molecules was also determined by MSI and/or conventional IHC<sup><xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR31">31</xref></sup>. Moreover, the selected samples were balanced for the HIV status and IHC group and downstream analyses were only performed with samples from South Africa in order to avoid a country specific bias.</p><p id="Par16">MSI confirmed the mRNA data demonstrating an aberrant T cell infiltration of the TME with an increased abundance of CD8<sup>+</sup> T cells. Despite these data were not related to an increased IFNG mRNA expression in tumor tissues, an activation of the canonical IFN-&#x003b3; signaling pathway was demonstrated with an increased Stat1 phosphorylation and ISG15 expression<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>. This discrepancy might be due to the fact that only local IFNG expression levels were analyzed. Under physiological conditions, IFN-&#x003b3; is secreted by T cells and NK cells<sup><xref ref-type="bibr" rid="CR33">33</xref>,<xref ref-type="bibr" rid="CR34">34</xref></sup> and stimulated by interleukins<sup><xref ref-type="bibr" rid="CR35">35</xref></sup> or pathogens, like infectious agents<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>. In the context of HIV, a strong systemic increase of IFN-&#x003b3; was shown in the acute infection<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>, while in the chronic disease contrary results were published ranging from decreased to sustained high serum levels of IFN-&#x003b3;<sup><xref ref-type="bibr" rid="CR38">38</xref>&#x02013;<xref ref-type="bibr" rid="CR40">40</xref></sup>. The activated IFN-&#x003b3; signaling in BC tissues of WLWH was validated using publicly available RNA expression data sets<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. Comparing RNA expression of BC specimens from WLWH and HIV negative BC patients, GSEA revealed an activation of several immune pathways including inflammatory response, TNF-&#x003b1; signaling via NF-kB, TGF-&#x003b2; signaling, IFN-&#x003b1; and IFN-&#x003b3; response. Recently, a dual role of IFN-&#x003b3; signaling with both synergistic and antagonistic effects has been described<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>. There is growing evidence that chronic IFN-&#x003b3; signaling inhibits the maintenance, clonal diversity and proliferation of T cells to restrict anti-tumor immunity, while the inhibition of IFN-&#x003b3; signaling leads to phenotypically less exhausted TILs, but impaired ICP inhibition<sup><xref ref-type="bibr" rid="CR42">42</xref>&#x02013;<xref ref-type="bibr" rid="CR44">44</xref></sup>. Additionally, HLA-I antigens are regulated by IFN-&#x003b3; signaling as well<sup><xref ref-type="bibr" rid="CR45">45</xref>,<xref ref-type="bibr" rid="CR46">46</xref></sup> and a slightly higher HLA-I expression in BC of WLWH was found in this patient cohort. Furthermore, the expression of several ICP molecules like PD-1<sup><xref ref-type="bibr" rid="CR47">47</xref></sup>, LAG3<sup><xref ref-type="bibr" rid="CR48">48</xref>,<xref ref-type="bibr" rid="CR49">49</xref></sup>, CTLA4<sup><xref ref-type="bibr" rid="CR50">50</xref></sup> and CD276<sup><xref ref-type="bibr" rid="CR51">51</xref>,<xref ref-type="bibr" rid="CR52">52</xref></sup> is increased by IFN-&#x003b3; signaling. In BC of WLWH an increased expression of these markers known to be associated with T cell exhaustion can already be found years prior to the manifestation of malignant diseases<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>. In our study, a higher expression of the ICP molecule CD276 was shown in the tumor tissue, particularly in WLWH - IS, which was associated with increased expression of T cell exhaustion markers CTLA4 and LAG3 in different T cell subpopulations. It is well known that CD276 inhibits the efficacy of CD8<sup>+</sup> cytotoxic T cells and drives tumor immune evasion that correlated with a decreased T cell infiltration within the TME<sup><xref ref-type="bibr" rid="CR53">53</xref>,<xref ref-type="bibr" rid="CR54">54</xref></sup>. An inverse correlation of increased frequencies of CD38<sup>+</sup>CD39<sup>+</sup>CD4<sup>+</sup> T cells and CD276 expression was found, which correlated with a better patients&#x02019; prognosis in CD276 deficient tumors<sup><xref ref-type="bibr" rid="CR53">53</xref></sup>. Interestingly, the more pronounced T cell exhaustion and CD276 expression in WLWH resulted in aberrant spatial T cell distribution showing a regional heterogeneity within the tumor. This was associated with a closer proximity between different T cell subsets independent from the CD4<sup>+</sup> T cell numbers in the peripheral blood. It has been shown that the spatial proximity of different immune cell subsets is associated with the initiation and the progression of malignant tumors<sup><xref ref-type="bibr" rid="CR55">55</xref>&#x02013;<xref ref-type="bibr" rid="CR57">57</xref></sup>. Moreover, multivariate cox regression analysis showed an independent prognostic value of both CD4 and CD276 expression. Due to its frequent overexpression, CD276 has already been identified as a valuable target for the treatment of malignant solid and hematological tumors<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR58">58</xref></sup>. Currently, a number of clinical trials using inhibitors including anti-CD276 antibody drug conjugates, or monoclonal antibodies alone or in combination with other checkpoint inhibitors and CAR-T cell therapies are ongoing<sup><xref ref-type="bibr" rid="CR59">59</xref>&#x02013;<xref ref-type="bibr" rid="CR62">62</xref></sup>.</p><p id="Par17">Taken together, our data show that WLWH with BC in SSA undergoing HAART showed (i) an activated IFN-&#x003b3; signaling in the TME, (ii) an upregulation of the ICP molecule CD276 and (iii) a more pronounced T cell exhaustion in particular in WLWH - IS and (iv) an aberrant T cell composition and distribution in WLWH that was independent from peripheral blood CD4<sup>+</sup> T cell numbers. Since the global prevalence of WLWH receiving HAART is increasing over time, non-AIDS-related cancers, such as BC, have become a significant cause of death among those patients<sup><xref ref-type="bibr" rid="CR63">63</xref></sup>. Therefore, the analysis of the TME and its influence on patients&#x02019; outcome is not only interesting in areas with an outstanding high HIV prevalence like SSA, but also worldwide. Thus, an increased understanding of the functional mechanisms of T cell exhaustion in the context of cancer in general, but in particular also in cancer patients living with HIV, is an urgent need that should be addressed in future studies. This should include a more comprehensive analysis of both the TME and the systemic immune status of the patients&#x02019; to enhance our understanding of the influence of chronic HIV in non-AIDS-related cancers. Furthermore, premature aging caused by the HIV infection and drug toxicity by both HAART and anti-cancer therapy including HAART-related liver damage are contributing factors that should be focused in future studies<sup><xref ref-type="bibr" rid="CR64">64</xref>&#x02013;<xref ref-type="bibr" rid="CR66">66</xref></sup>.</p></sec><sec id="Sec7"><title>Methods</title><sec id="Sec8"><title>Ethical statement</title><p id="Par18">This research complies with the ethical regulations. All patients provided written informed consent. Local ethical institutions (Ethical Committee of the Martin Luther University Halle-Wittenberg, Ministry of Health and Social Services of Namibia, and the Institutional Review Board of University of the Witwatersrand, Gauteng) approved the scientific use of the FFPE tissue samples (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Overview of the local ethical approvals</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Institution</th><th>Country</th><th>Date of approval</th><th>Identification number</th></tr></thead><tbody><tr><td>Martin Luther University, Halle-Wittenberg</td><td>Germany</td><td>06/06/2014</td><td>2014-57</td></tr><tr><td>School of Anatomical Pathology, National Health Laboratory Services</td><td>South Africa</td><td>27/07/2014</td><td>M140754</td></tr><tr><td>IARC</td><td>France</td><td>&#x02014;</td><td>IEC13-19, IEC15-18</td></tr><tr><td>Ministry of Health and Social Services of Namibia</td><td>Namibia</td><td>2017</td><td>17/3/3</td></tr><tr><td>University of the Witwatersrand, Gauteng,</td><td>South Africa</td><td>&#x02014;</td><td>M150345</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec9"><title>Patients&#x02019; characteristics and study design</title><p id="Par19">We embedded this study within two BC cohorts in Southern Africa, i.e., the ABC-DO study and SABCHO<sup><xref ref-type="bibr" rid="CR67">67</xref>,<xref ref-type="bibr" rid="CR68">68</xref></sup>, to avail of tumor specimens, clinical, epidemiological, treatment and highly complete active follow-up data. These two African BC cohorts were diagnosed during 2015&#x02013;2021 and each include 2000 to 3000 BC patients newly diagnosed across multiple hospitals and for ABC-DO study, countries. For the purpose of the present study, we identified a subset of black women from two countries with a high HIV prevalence i.e., South Africa and Namibia, whose tumor specimens had been retrieved and were of good quality. We included as many BC specimens from WLWH as possible, and for comparative purposes, not all but at least as many HIV negative women. HIV status had already been ascertained at the time of diagnosis, based on self-reports in Namibia and, in South Africa, from medical records based on the enzyme-linked immunosorbent assay through the National Health Laboratory Services. In total, we analyzed formalin-fixed and paraffin-embedded (FFPE) tissue blocks of 296 women (291 with survival data), comprising 218 women from South Africa (105 HIV positive and 113 HIV negative) and 78 from Namibia (12 HIV positive and 66 HIV negative). Of this selected set, 117 tumors were from WLWH (39.5%) and 179 from HIV negative BC patients (60.5%). Clinical data available for all women include stage a diagnosis, such as TNM stage according to the Union for International Cancer Control (UICC). A simplified stage was used for tumors &#x0003e;5.0&#x02009;cm diameter and/or with known metastasis refer to advanced stage. The CD4<sup>+</sup> T cell numbers and the viral load in peripheral blood were known from 103 patients at the time point of BC diagnosis.</p></sec><sec id="Sec10"><title>Histopathology and immunohistochemistry</title><p id="Par20">Histopathological diagnoses of BC were made according to the WHO classification of Breast Tumors 5th edition<sup><xref ref-type="bibr" rid="CR69">69</xref></sup>, including histopathological grading according Elston and Ellis<sup><xref ref-type="bibr" rid="CR70">70</xref></sup>. All samples were re-analyzed by two pathologists independently using conventional IHC using antibodies (Ab) directed against the ER, PR, HER2 and Ki67 (Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">3</xref>). IHC staining was performed on a Bond III automated immunostainer (Leica Biosystems Nussloch GmbH, Wetzlar, Germany) using the Bond Polymer Refine Detection Kit (DS9800-CN). BC subtypes were classified according to the surrogate IHC group classification using hormone receptor expression of ER and PR, the HER2 status as well as Ki67 proliferation index including the following IHC groups: Luminal A-like, Luminal B-like, HER2 positive (HER2&#x02009;+&#x02009;), triple negative BC (TNBC)<sup><xref ref-type="bibr" rid="CR71">71</xref></sup>. ER and PR negativity was defined as receptor expression of &#x0003c;1% of tumor cells according to the ASCO guidelines<sup><xref ref-type="bibr" rid="CR72">72</xref></sup>. HER2 expression with DAKO score 2 (equivocal) underwent confirmatory HER2 in-situ hybridization (ISH) according to the ASCO guidelines<sup><xref ref-type="bibr" rid="CR73">73</xref></sup>. The number of tumor infiltrating lymphocytes (TIL) was analyzed on hematoxylin and eosin (H&#x00026;E) slides as described elsewhere<sup><xref ref-type="bibr" rid="CR27">27</xref></sup> and scored by two pathologists independently.</p></sec><sec id="Sec11"><title>ICP expression and immune cell infiltration analysis</title><p id="Par21">For ICP expression and TIL subpopulation analysis 48 samples from South Africa were used (equally balanced for HIV status and hormone receptor status). These samples were stained with an antibody directed against CD276/B7-H3 (details in Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">2</xref>) according to the manufacturer&#x02019;s instructions. The qualitative and quantitative expression was determined employing the H score<sup><xref ref-type="bibr" rid="CR74">74</xref></sup>. Analysis was performed by two pathologists independently.</p><p id="Par22">Moreover, the frequency and localization of the different immune cell subpopulations and cancer cells as well as the expression of several immune markers was evaluated by multispectral imaging (MSI). The multispectral staining procedure was performed using standard protocols<sup><xref ref-type="bibr" rid="CR75">75</xref></sup>. The following two antibody panels were employed: 1<sup>st</sup> panel: CD3, CD8, FoxP3, CD69, programmed cell death protein 1 (PD-1), lymphocyte-activation gene 3 (LAG-3), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and indolamine-2,3-dioxygenase (IDO)-1; 2nd panel: CD3, Pan-cytokeratin (panCK), phosphorylated signal transducer and activator of transcription 1 (pStat1), Interferon-stimulated gene 15 (ISG15), human leukocyte antigen (HLA) class I heavy chain (HC), HLA-G, and CXC motif chemokine receptor 4 (CXCR4) (Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">3</xref>). For imaging the PhenoImager HT (Akoya Biosciences, Marlborough, USA) was employed and three areas (each 3744&#x02009;&#x000d7;&#x02009;2808 pixel, 0.5&#x02009;&#x000b5;m/pixel) were selected for cell segmentation and subsequent analysis. Cell segmentation and phenotyping were performed using the inform software (Version 2.6, Akoya biosciences, USA). The frequency and spatial distribution of cell populations were analyzed using an R script (<ext-link ext-link-type="uri" xlink:href="https://github.com/akoyabio">https://github.com/akoyabio</ext-link>).</p></sec><sec id="Sec12"><title>RNA isolation and gene expression analysis</title><p id="Par23">Prior to RNA isolation, FFPE specimens were microdissected. For RNA isolation, two to four 10-&#x000b5;m thick tissue slides were used. Deparaffinization of FFPE tissues was performed 2 times with xylene for 5&#x02009;min, followed by incubation in 96% and 70% ethanol for 2&#x02009;min each. Proteinase K digestion was performed for up to 2&#x02009;h at room temperature followed by 15&#x02009;min at 80&#x02009;&#x000b0;C. RNA was isolated with miRNeasy Mini FFPE Kit (Qiagen, Venlo, The Netherlands) according to the manufacturer&#x02019;s instructions. RNA expression analysis was performed using the NanoString Assay according to the hybridization protocol for the nCounter XT CodeSet Gene Expression Assay (NanoString nCounter, Seattle, WA, USA). Raw expression data was analyzed with the nCounter Expression Data Analysis Guide (MAN-C0011-04 from 2017). Data import, quality control and normalization of expression levels were conducted with the nSolver software version 4 (NanoString Technologies) and the expression levels were evaluated with the NanoStringNorm R package (<ext-link ext-link-type="uri" xlink:href="https://github.com/sgrote/NanoStringNormalizeR/">https://github.com/sgrote/NanoStringNormalizeR/</ext-link>). Background subtraction from raw transcript counts was achieved with negative controls. After reference normalization (dividing the geometric mean of six references genes: ACTB, G6PD, RPLP0, TBP, TFRC and UBB), expression data was log2-transformed and considered in all downstream analyses. The NCBI accession numbers of RNAs analyzed are provided in Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">1</xref>.</p></sec><sec id="Sec13"><title>Analysis of the publicly available data set GSE149156</title><p id="Par24">Normalized gene expression data of GSE149156<sup><xref ref-type="bibr" rid="CR21">21</xref></sup> were downloaded of from Gene Expression Omnibus (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/">https://www.ncbi.nlm.nih.gov/geo/</ext-link>). Differential gene expression analysis of BC specimens of WLWH (<italic>n</italic>&#x02009;=&#x02009;6) and HIV negative patients (<italic>n</italic>&#x02009;=&#x02009;3) was performed using PyDESeq2 package in Python<sup><xref ref-type="bibr" rid="CR76">76</xref></sup>. For gene set enrichment analysis (GSEA), prerank function of GSEApy (PMID: 36426870) and the MSigDB_Hallmark_2020 gene set (<ext-link ext-link-type="uri" xlink:href="https://www.gsea-msigdb.org/gsea/msigdb/collections.jsp">https://www.gsea-msigdb.org/gsea/msigdb/collections.jsp</ext-link>) was used. Differentially expressed genes were not filtered for statistical significance before ranking. The normalized enrichment score (NES) and the false discovery rate (FDR) were calculated for all gene sets. Volcano plots were created with python using Pandas, NumPy, SciPy and Metplotlib packages. Means and standard deviations were calculated for each gene and independent t-tests were performed. Log fold changes and &#x02212;log10(p-values) were computed and the significant differentially expressed genes (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, logFC&#x02009;&#x0003e;&#x02009;2) were highlighted. The immune related genes for the immune focused volcano plot are summarized in Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">2</xref>.</p></sec><sec id="Sec14"><title>Statistics</title><p id="Par25">The Mann&#x02013;Whitney U test was employed to compare clinical and immunological data between different HIV status and IHC groups. A multivariate logistic regression (generalized linear model, binomial family) was used to estimate odds ratios (OR) and confidence intervals (CI) concerning the effects of age (continuous variable, by year), stage (binary variable, advanced vs. early), IHC groups (categorical variable) and gene expression of selected genes (<italic>n</italic>&#x02009;=&#x02009;41, Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">3</xref>) with HIV status. Association of a positive HIV status and increasing variable values (age, or gene expression), or as compared to the reference category (stage and IHC groups with e.g., &#x02018;Luminal A-like&#x02019; in the case of IHC groups) is given with OR. Regressions were performed using the Statsmodels library for Python (<ext-link ext-link-type="uri" xlink:href="http://www.statsmodels.org">www.statsmodels.org</ext-link>). Linear correlations between continuous variables (gene expression) were estimated as Pearson&#x02019;s correlations. Survival analyses were performed for 291 patients (maximum follow-up time of 72 months) with differences calculated with Cox proportional hazard models (adjusted for confounding factors) regarding OS as endpoint. Except when stated otherwise, all statistical analyses were performed using IBM SPSS Statistics 25 or GraphPad Prism v9.</p></sec><sec id="Sec15"><title>Reporting summary</title><p id="Par26">Further information on research design is available in the&#x000a0;<xref rid="MOESM2" ref-type="media">Nature Portfolio Reporting Summary</xref> linked to this article.</p></sec></sec><sec id="Sec16" sec-type="supplementary-material"><title>Supplementary information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41467_2025_59408_MOESM1_ESM.pdf"><caption><p>Supplementary Information</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="41467_2025_59408_MOESM2_ESM.pdf"><caption><p>Reporting Summary</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="41467_2025_59408_MOESM3_ESM.pdf"><caption><p>Transparent Peer Review file</p></caption></media></supplementary-material>
</p></sec><sec id="Sec17" sec-type="supplementary-material"><title>Source data</title><p>
<supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="41467_2025_59408_MOESM4_ESM.xlsx"><caption><p>Source data</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><sec><title>Supplementary information</title><p>The online version contains supplementary material available at 10.1038/s41467-025-59408-8.</p></sec><ack><title>Acknowledgements</title><p>We want to thank all patients who provided tumor samples and the pathology staff. This work was supported by grants from the Else-Kr&#x000f6;ner-Foundation (EJK, 2018_HA31SP), Susan G. Komen-Foundation (EJK, GTDR16378013, V.M., IIR13264158), German Cancer Aid (B.S., Integrate-TN, 70113450), the German Research Council (BS, Se581/33-1), German Academic Exchange Service (EJK, ID57216764), Ministry for Economic Cooperation and Development and the Else-Kr&#x000f6;ner-Fresenius Foundation (EJK, ID81256434), Hoffmann-La Roche Ltd (EJK, 27.5.2014) and the National Cancer Institute (V.M., R01CA244559). Disclaimer: Where authors are identified as personnel of the International Agency for Research on Cancer / World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of these organisations.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>All authors agreed on the final version of the manuscript. The samples and clinical data were collected by E.B., A.Z., H.C., N.M., W.C.C., V.M., M.J. E.J.K., C.W., M.J., M.C. and B.S. mentored the team. Analyses were performed by M.B., P.S., A.W., S.K., M.V. and I.S.S. The original draft was written by M.B., P.S., M.J., V.M., E.J.K. and B.S.</p></notes><notes notes-type="peer-review"><title>Peer review</title><sec id="FPar1"><title>Peer review information</title><p id="Par27"><italic>Nature Communications</italic> thanks Marcelo Soares who co-reviewed with Gislaine Curty and the other anonymous reviewer(s) for their contribution to the peer review of this work. A peer review file is available.</p></sec></notes><notes notes-type="funding-information"><title>Funding</title><p>Open Access funding enabled and organized by Projekt DEAL.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>All data are included in the Supplementary Information or available from the authors, as are unique reagents used in this Article. The raw numbers for charts and graphs are available in the Source Data file whenever possible. Further data generated are available upon request to the corresponding author or ABC-DO/SABCHO study PIs. The normalized RNA expression data generated in this study have been provided in the source data file.&#x000a0;<xref ref-type="sec" rid="Sec17">Source data</xref> are provided with this paper.</p></notes><notes id="FPar2" notes-type="COI-statement"><title>Competing interests</title><p id="Par28">The authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Ferlay</surname><given-names>J</given-names></name><etal/></person-group><article-title>Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods</article-title><source>Int. J. Cancer</source><year>2019</year><volume>144</volume><fpage>1941</fpage><lpage>1953</lpage><pub-id pub-id-type="doi">10.1002/ijc.31937</pub-id><pub-id pub-id-type="pmid">30350310</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Ferlay, J. et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. <italic>Int. J. Cancer</italic><bold>144</bold>, 1941&#x02013;1953 (2019).<pub-id pub-id-type="pmid">30350310</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Hamdi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Cancer in Africa: the untold story</article-title><source>Front. Oncol.</source><year>2021</year><volume>11</volume><fpage>650117</fpage><pub-id pub-id-type="doi">10.3389/fonc.2021.650117</pub-id><pub-id pub-id-type="pmid">33937056</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Hamdi, Y. et al. Cancer in Africa: the untold story. <italic>Front. Oncol.</italic><bold>11</bold>, 650117 (2021).<pub-id pub-id-type="pmid">33937056</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>H</given-names></name><etal/></person-group><article-title>Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality Worldwide for 36 Cancers in 185 Countries</article-title><source>CA Cancer J. Clin.</source><year>2021</year><volume>71</volume><fpage>209</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.3322/caac.21660</pub-id><pub-id pub-id-type="pmid">33538338</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality Worldwide for 36 Cancers in 185 Countries. <italic>CA Cancer J. Clin.</italic><bold>71</bold>, 209&#x02013;249 (2021).<pub-id pub-id-type="pmid">33538338</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Weiner</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Characteristics and follow-up of metastatic breast cancer in Ethiopia: a cohort study of 573 women</article-title><source>Breast Edinb. Scotl.</source><year>2018</year><volume>42</volume><fpage>23</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.breast.2018.08.095</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Weiner, C. M. et al. Characteristics and follow-up of metastatic breast cancer in Ethiopia: a cohort study of 573 women. <italic>Breast Edinb. Scotl.</italic><bold>42</bold>, 23&#x02013;30 (2018).</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>McKenzie</surname><given-names>F</given-names></name><etal/></person-group><article-title>Drivers of advanced stage at breast cancer diagnosis in the multicountry African breast cancer - disparities in outcomes (ABC-DO) study</article-title><source>Int. J. Cancer</source><year>2018</year><volume>142</volume><fpage>1568</fpage><lpage>1579</lpage><pub-id pub-id-type="doi">10.1002/ijc.31187</pub-id><pub-id pub-id-type="pmid">29197068</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">McKenzie, F. et al. Drivers of advanced stage at breast cancer diagnosis in the multicountry African breast cancer - disparities in outcomes (ABC-DO) study. <italic>Int. J. Cancer</italic><bold>142</bold>, 1568&#x02013;1579 (2018).<pub-id pub-id-type="pmid">29197068</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>McCormack</surname><given-names>V</given-names></name><etal/></person-group><article-title>Breast cancer survival and survival gap apportionment in sub-Saharan Africa (ABC-DO): a prospective cohort study</article-title><source>Lancet Glob. Health</source><year>2020</year><volume>8</volume><fpage>e1203</fpage><lpage>e1212</lpage><pub-id pub-id-type="doi">10.1016/S2214-109X(20)30261-8</pub-id><pub-id pub-id-type="pmid">32827482</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">McCormack, V. et al. Breast cancer survival and survival gap apportionment in sub-Saharan Africa (ABC-DO): a prospective cohort study. <italic>Lancet Glob. Health</italic><bold>8</bold>, e1203&#x02013;e1212 (2020).<pub-id pub-id-type="pmid">32827482</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>M</given-names></name><etal/></person-group><article-title>Regional variation in the tumor microenvironment, immune escape and prognostic factors in breast cancer in Sub-Saharan Africa</article-title><source>Cancer Immunol. Res.</source><year>2023</year><volume>11</volume><fpage>720</fpage><lpage>731</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-22-0795</pub-id><pub-id pub-id-type="pmid">37058582</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Bauer, M. et al. Regional variation in the tumor microenvironment, immune escape and prognostic factors in breast cancer in Sub-Saharan Africa. <italic>Cancer Immunol. Res.</italic><bold>11</bold>, 720&#x02013;731 (2023).<pub-id pub-id-type="pmid">37058582</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Miyashita</surname><given-names>M</given-names></name><etal/></person-group><article-title>Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry and African ancestry patient populations</article-title><source>Breast Cancer Res.</source><year>2023</year><volume>25</volume><fpage>58</fpage><pub-id pub-id-type="doi">10.1186/s13058-023-01627-2</pub-id><pub-id pub-id-type="pmid">37231433</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Miyashita, M. et al. Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry and African ancestry patient populations. <italic>Breast Cancer Res.</italic><bold>25</bold>, 58 (2023).<pub-id pub-id-type="pmid">37231433</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Martini</surname><given-names>R</given-names></name><etal/></person-group><article-title>African ancestry-associated gene expression profiles in triple-negative breast cancer underlie altered tumor biology and clinical outcome in Women of African Descent</article-title><source>Cancer Discov.</source><year>2022</year><volume>12</volume><fpage>2530</fpage><lpage>2551</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-22-0138</pub-id><pub-id pub-id-type="pmid">36121736</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Martini, R. et al. African ancestry-associated gene expression profiles in triple-negative breast cancer underlie altered tumor biology and clinical outcome in Women of African Descent. <italic>Cancer Discov.</italic><bold>12</bold>, 2530&#x02013;2551 (2022).<pub-id pub-id-type="pmid">36121736</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Grover</surname><given-names>S</given-names></name><etal/></person-group><article-title>Breast cancer and HIV in Sub-Saharan Africa: a complex relationship</article-title><source>J. Glob. Oncol.</source><year>2018</year><volume>4</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">30532993</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Grover, S. et al. Breast cancer and HIV in Sub-Saharan Africa: a complex relationship. <italic>J. Glob. Oncol.</italic><bold>4</bold>, 1&#x02013;11 (2018). Sep.<pub-id pub-id-type="pmid">30532993</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Haeuser</surname><given-names>E</given-names></name><etal/></person-group><article-title>Mapping age- and sex-specific HIV prevalence in adults in sub-Saharan Africa, 2000-2018</article-title><source>BMC Med.</source><year>2022</year><volume>20</volume><fpage>488</fpage><pub-id pub-id-type="doi">10.1186/s12916-022-02639-z</pub-id><pub-id pub-id-type="pmid">36529768</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Haeuser, E. et al. Mapping age- and sex-specific HIV prevalence in adults in sub-Saharan Africa, 2000-2018. <italic>BMC Med.</italic><bold>20</bold>, 488 (2022).<pub-id pub-id-type="pmid">36529768</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>DY</given-names></name><etal/></person-group><article-title>HAART in HIV/AIDS treatments: future trends</article-title><source>Infect. Disord. Drug Targets</source><year>2018</year><volume>18</volume><fpage>15</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.2174/1871526517666170505122800</pub-id><pub-id pub-id-type="pmid">28474549</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Lu, D. Y. et al. HAART in HIV/AIDS treatments: future trends. <italic>Infect. Disord. Drug Targets</italic><bold>18</bold>, 15&#x02013;22 (2018).<pub-id pub-id-type="pmid">28474549</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Agarwal-Jans</surname><given-names>S</given-names></name></person-group><article-title>Timeline: HIV</article-title><source>Cell</source><year>2020</year><volume>183</volume><fpage>550</fpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.09.004</pub-id><pub-id pub-id-type="pmid">33064990</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Agarwal-Jans, S. Timeline: HIV. <italic>Cell</italic><bold>183</bold>, 550 (2020).<pub-id pub-id-type="pmid">33064990</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><collab>GBD 2017 HIV collaborators.</collab></person-group><article-title>Global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017</article-title><source>Lancet Hiv.</source><year>2019</year><volume>6</volume><fpage>e831</fpage><lpage>e859</lpage><pub-id pub-id-type="doi">10.1016/S2352-3018(19)30196-1</pub-id><pub-id pub-id-type="pmid">31439534</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">GBD 2017 HIV collaborators. Global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. <italic>Lancet Hiv.</italic><bold>6</bold>, e831&#x02013;e859 (2019).<pub-id pub-id-type="pmid">31439534</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Chasimpha</surname><given-names>S</given-names></name><etal/></person-group><article-title>Disparities in breast cancer survival between women with and without HIV across sub-Saharan Africa (ABC-DO): a prospective, cohort study</article-title><source>Lancet Hiv.</source><year>2022</year><volume>9</volume><fpage>e160</fpage><lpage>e171</lpage><pub-id pub-id-type="doi">10.1016/S2352-3018(21)00326-X</pub-id><pub-id pub-id-type="pmid">35245508</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Chasimpha, S. et al. Disparities in breast cancer survival between women with and without HIV across sub-Saharan Africa (ABC-DO): a prospective, cohort study. <italic>Lancet Hiv.</italic><bold>9</bold>, e160&#x02013;e171 (2022).<pub-id pub-id-type="pmid">35245508</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Chasimpha</surname><given-names>S</given-names></name><etal/></person-group><article-title>Survival disparities between patients with breast cancer with and without HIV: a research framework</article-title><source>JCO Glob. Oncol.</source><year>2023</year><volume>9</volume><fpage>e2200330</fpage><pub-id pub-id-type="doi">10.1200/GO.22.00330</pub-id><pub-id pub-id-type="pmid">37075268</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Chasimpha, S. et al. Survival disparities between patients with breast cancer with and without HIV: a research framework. <italic>JCO Glob. Oncol.</italic><bold>9</bold>, e2200330 (2023).<pub-id pub-id-type="pmid">37075268</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Ayeni</surname><given-names>OA</given-names></name><etal/></person-group><article-title>Impact of HIV infection on survival among women with stage I-III breast cancer: results from the South African breast cancer and HIV outcomes study</article-title><source>Int. J. Cancer</source><year>2022</year><volume>151</volume><fpage>209</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1002/ijc.33981</pub-id><pub-id pub-id-type="pmid">35218568</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Ayeni, O. A. et al. Impact of HIV infection on survival among women with stage I-III breast cancer: results from the South African breast cancer and HIV outcomes study. <italic>Int. J. Cancer</italic><bold>151</bold>, 209&#x02013;221 (2022).<pub-id pub-id-type="pmid">35218568</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Dubner</surname><given-names>J</given-names></name><etal/></person-group><article-title>The association of HIV status with triple-negative breast cancer in patients with breast cancer in South Africa: a cross-sectional analysis of case-only data from a prospective cohort study</article-title><source>Lancet Glob. Health</source><year>2024</year><volume>12</volume><fpage>e1993</fpage><lpage>e2002</lpage><pub-id pub-id-type="doi">10.1016/S2214-109X(24)00376-0</pub-id><pub-id pub-id-type="pmid">39577973</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Dubner, J. et al. The association of HIV status with triple-negative breast cancer in patients with breast cancer in South Africa: a cross-sectional analysis of case-only data from a prospective cohort study. <italic>Lancet Glob. Health</italic><bold>12</bold>, e1993&#x02013;e2002 (2024).<pub-id pub-id-type="pmid">39577973</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Chaudhary</surname><given-names>O</given-names></name><etal/></person-group><article-title>Patients with HIV-associated cancers have evidence of increased T cell dysfunction and exhaustion prior to cancer diagnosis</article-title><source>J. Immunother. Cancer</source><year>2022</year><volume>10</volume><fpage>e004564</fpage><pub-id pub-id-type="doi">10.1136/jitc-2022-004564</pub-id><pub-id pub-id-type="pmid">35470232</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Chaudhary, O. et al. Patients with HIV-associated cancers have evidence of increased T cell dysfunction and exhaustion prior to cancer diagnosis. <italic>J. Immunother. Cancer</italic><bold>10</bold>, e004564 (2022).<pub-id pub-id-type="pmid">35470232</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Sperk</surname><given-names>M</given-names></name><name><surname>Domselaar</surname><given-names>Rvan</given-names></name><name><surname>Neogi</surname><given-names>U</given-names></name></person-group><article-title>Immune checkpoints as the immune system regulators and potential biomarkers in HIV-1 Iinfection</article-title><source>Int. J. Mol. Sci.</source><year>2018</year><volume>19</volume><fpage>2000</fpage><pub-id pub-id-type="doi">10.3390/ijms19072000</pub-id><pub-id pub-id-type="pmid">29987244</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Sperk, M., Domselaar, Rvan &#x00026; Neogi, U. Immune checkpoints as the immune system regulators and potential biomarkers in HIV-1 Iinfection. <italic>Int. J. Mol. Sci.</italic><bold>19</bold>, 2000 (2018).<pub-id pub-id-type="pmid">29987244</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Curty</surname><given-names>G</given-names></name><etal/></person-group><article-title>Human endogenous retrovirus expression is upregulated in the breast cancer microenvironment of HIV infected women: a pilot study</article-title><source>Front. Oncol.</source><year>2020</year><volume>10</volume><fpage>553983</fpage><pub-id pub-id-type="doi">10.3389/fonc.2020.553983</pub-id><pub-id pub-id-type="pmid">33194615</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Curty, G. et al. Human endogenous retrovirus expression is upregulated in the breast cancer microenvironment of HIV infected women: a pilot study. <italic>Front. Oncol.</italic><bold>10</bold>, 553983 (2020).<pub-id pub-id-type="pmid">33194615</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Engels</surname><given-names>EA</given-names></name><etal/></person-group><article-title>Trends in cancer risk among people with AIDS in the United States 1980-2002</article-title><source>AIDS Lond. Engl.</source><year>2006</year><volume>20</volume><fpage>1645</fpage><lpage>1654</lpage><pub-id pub-id-type="doi">10.1097/01.aids.0000238411.75324.59</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Engels, E. A. et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. <italic>AIDS Lond. Engl.</italic><bold>20</bold>, 1645&#x02013;1654 (2006).</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname><given-names>D</given-names></name></person-group><article-title>Hallmarks of cancer: new dimensions</article-title><source>Cancer Discov.</source><year>2022</year><volume>12</volume><fpage>31</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-21-1059</pub-id><pub-id pub-id-type="pmid">35022204</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Hanahan, D. Hallmarks of cancer: new dimensions. <italic>Cancer Discov.</italic><bold>12</bold>, 31&#x02013;46 (2022).<pub-id pub-id-type="pmid">35022204</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>El Tekle</surname><given-names>G</given-names></name><name><surname>Garrett</surname><given-names>WS</given-names></name></person-group><article-title>Bacteria in cancer initiation, promotion and progression</article-title><source>Nat. Rev. Cancer</source><year>2023</year><volume>23</volume><fpage>600</fpage><lpage>618</lpage><pub-id pub-id-type="doi">10.1038/s41568-023-00594-2</pub-id><pub-id pub-id-type="pmid">37400581</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">El Tekle, G. &#x00026; Garrett, W. S. Bacteria in cancer initiation, promotion and progression. <italic>Nat. Rev. Cancer</italic><bold>23</bold>, 600&#x02013;618 (2023).<pub-id pub-id-type="pmid">37400581</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Costanzo</surname><given-names>M</given-names></name><name><surname>De Giglio</surname><given-names>MAR</given-names></name><name><surname>Roviello</surname><given-names>GN</given-names></name></person-group><article-title>Deciphering the relationship between SARS-CoV-2 and cancer</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><fpage>7803</fpage><pub-id pub-id-type="doi">10.3390/ijms24097803</pub-id><pub-id pub-id-type="pmid">37175509</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Costanzo, M., De Giglio, M. A. R. &#x00026; Roviello, G. N. Deciphering the relationship between SARS-CoV-2 and cancer. <italic>Int. J. Mol. Sci.</italic><bold>24</bold>, 7803 (2023).<pub-id pub-id-type="pmid">37175509</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Akbari</surname><given-names>E</given-names></name><name><surname>Milani</surname><given-names>A</given-names></name><name><surname>Seyedinkhorasani</surname><given-names>M</given-names></name><name><surname>Bolhassani</surname><given-names>A</given-names></name></person-group><article-title>HPV co-infections with other pathogens in cancer development: a comprehensive review</article-title><source>J. Med. Virol.</source><year>2023</year><volume>95</volume><fpage>e29236</fpage><pub-id pub-id-type="doi">10.1002/jmv.29236</pub-id><pub-id pub-id-type="pmid">37997472</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Akbari, E., Milani, A., Seyedinkhorasani, M. &#x00026; Bolhassani, A. HPV co-infections with other pathogens in cancer development: a comprehensive review. <italic>J. Med. Virol.</italic><bold>95</bold>, e29236 (2023).<pub-id pub-id-type="pmid">37997472</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Salgado</surname><given-names>R</given-names></name><etal/></person-group><article-title>The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014</article-title><source>Ann. Oncol.</source><year>2015</year><volume>26</volume><fpage>259</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdu450</pub-id><pub-id pub-id-type="pmid">25214542</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Salgado, R. et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. <italic>Ann. Oncol.</italic><bold>26</bold>, 259&#x02013;271 (2015).<pub-id pub-id-type="pmid">25214542</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>YP</given-names></name><name><surname>Ke</surname><given-names>YL</given-names></name><name><surname>Li</surname><given-names>X</given-names></name></person-group><article-title>Prognostic value of CD8+ tumor-infiltrating T cells in patients with breast cancer: a systematic review and meta-analysis</article-title><source>Oncol. Lett.</source><year>2023</year><volume>25</volume><fpage>39</fpage><pub-id pub-id-type="doi">10.3892/ol.2022.13625</pub-id><pub-id pub-id-type="pmid">36589661</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Sun, Y. P., Ke, Y. L. &#x00026; Li, X. Prognostic value of CD8+ tumor-infiltrating T cells in patients with breast cancer: a systematic review and meta-analysis. <italic>Oncol. Lett.</italic><bold>25</bold>, 39 (2023).<pub-id pub-id-type="pmid">36589661</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Egelston</surname><given-names>CA</given-names></name><etal/></person-group><article-title>Tumor-infiltrating exhausted CD8+ T cells dictate reduced survival in premenopausal estrogen receptor&#x02013;positive breast cancer</article-title><source>JCI Insight</source><year>2022</year><volume>7</volume><fpage>e153963</fpage><pub-id pub-id-type="doi">10.1172/jci.insight.153963</pub-id><pub-id pub-id-type="pmid">35132960</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Egelston, C. A. et al. Tumor-infiltrating exhausted CD8+ T cells dictate reduced survival in premenopausal estrogen receptor&#x02013;positive breast cancer. <italic>JCI Insight</italic><bold>7</bold>, e153963 (2022).<pub-id pub-id-type="pmid">35132960</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Koussounadis</surname><given-names>A</given-names></name><name><surname>Langdon</surname><given-names>SP</given-names></name><name><surname>Um</surname><given-names>IH</given-names></name><name><surname>Harrison</surname><given-names>DJ</given-names></name><name><surname>Smith</surname><given-names>VA</given-names></name></person-group><article-title>Relationship between differentially expressed mRNA and mRNA-protein correlations in a xenograft model system</article-title><source>Sci. Rep.</source><year>2015</year><volume>5</volume><fpage>10775</fpage><pub-id pub-id-type="doi">10.1038/srep10775</pub-id><pub-id pub-id-type="pmid">26053859</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Koussounadis, A., Langdon, S. P., Um, I. H., Harrison, D. J. &#x00026; Smith, V. A. Relationship between differentially expressed mRNA and mRNA-protein correlations in a xenograft model system. <italic>Sci. Rep.</italic><bold>5</bold>, 10775 (2015).<pub-id pub-id-type="pmid">26053859</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Gry</surname><given-names>M</given-names></name><etal/></person-group><article-title>Correlations between RNA and protein expression profiles in 23 human cell lines</article-title><source>BMC Genom.</source><year>2009</year><volume>10</volume><fpage>365</fpage><pub-id pub-id-type="doi">10.1186/1471-2164-10-365</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Gry, M. et al. Correlations between RNA and protein expression profiles in 23 human cell lines. <italic>BMC Genom.</italic><bold>10</bold>, 365 (2009).</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Negishi</surname><given-names>H</given-names></name><name><surname>Taniguchi</surname><given-names>T</given-names></name><name><surname>Yanai</surname><given-names>H</given-names></name></person-group><article-title>The Interferon (IFN) class of cytokines and the IFN Regulatory Factor (IRF) transcription factor family</article-title><source>Cold Spring Harb. Perspect. Biol.</source><year>2018</year><volume>10</volume><fpage>a028423</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a028423</pub-id><pub-id pub-id-type="pmid">28963109</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Negishi, H., Taniguchi, T. &#x00026; Yanai, H. The Interferon (IFN) class of cytokines and the IFN Regulatory Factor (IRF) transcription factor family. <italic>Cold Spring Harb. Perspect. Biol.</italic><bold>10</bold>, a028423 (2018).<pub-id pub-id-type="pmid">28963109</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Bancroft</surname><given-names>GJ</given-names></name><name><surname>Schreiber</surname><given-names>RD</given-names></name><name><surname>Bosma</surname><given-names>GC</given-names></name><name><surname>Bosma</surname><given-names>MJ</given-names></name><name><surname>Unanue</surname><given-names>ER</given-names></name></person-group><article-title>A T cell-independent mechanism of macrophage activation by interferon-gamma</article-title><source>J. Immunol.</source><year>1987</year><volume>139</volume><fpage>1104</fpage><lpage>1107</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.139.4.1104</pub-id><pub-id pub-id-type="pmid">3112223</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Bancroft, G. J., Schreiber, R. D., Bosma, G. C., Bosma, M. J. &#x00026; Unanue, E. R. A T cell-independent mechanism of macrophage activation by interferon-gamma. <italic>J. Immunol.</italic><bold>139</bold>, 1104&#x02013;1107 (1987).<pub-id pub-id-type="pmid">3112223</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Maimela</surname><given-names>NR</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><article-title>Fates of CD8+ T cells in tumor microenvironment</article-title><source>Comput. Struct. Biotechnol. J.</source><year>2019</year><volume>17</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.csbj.2018.11.004</pub-id><pub-id pub-id-type="pmid">30581539</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Maimela, N. R., Liu, S. &#x00026; Zhang, Y. Fates of CD8+ T cells in tumor microenvironment. <italic>Comput. Struct. Biotechnol. J.</italic><bold>17</bold>, 1&#x02013;13 (2019).<pub-id pub-id-type="pmid">30581539</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Kannan</surname><given-names>Y</given-names></name><etal/></person-group><article-title>I&#x003ba;B&#x003b6; augments IL-12- and IL-18-mediated IFN-&#x003b3; production in human NK cells</article-title><source>Blood</source><year>2011</year><volume>117</volume><fpage>2855</fpage><lpage>2863</lpage><pub-id pub-id-type="doi">10.1182/blood-2010-07-294702</pub-id><pub-id pub-id-type="pmid">21224476</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Kannan, Y. et al. I&#x003ba;B&#x003b6; augments IL-12- and IL-18-mediated IFN-&#x003b3; production in human NK cells. <italic>Blood</italic><bold>117</bold>, 2855&#x02013;2863 (2011).<pub-id pub-id-type="pmid">21224476</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Hosking</surname><given-names>MP</given-names></name><name><surname>Flynn</surname><given-names>CT</given-names></name><name><surname>Whitton</surname><given-names>JL</given-names></name></person-group><article-title>Antigen-specific naive CD8+ T cells produce a single pulse of IFN-&#x003b3; in vivo within hours of infection, but without antiviral effect</article-title><source>J. Immunol.</source><year>2014</year><volume>193</volume><fpage>1873</fpage><lpage>1885</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1400348</pub-id><pub-id pub-id-type="pmid">25015828</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Hosking, M. P., Flynn, C. T. &#x00026; Whitton, J. L. Antigen-specific naive CD8+ T cells produce a single pulse of IFN-&#x003b3; in vivo within hours of infection, but without antiviral effect. <italic>J. Immunol.</italic><bold>193</bold>, 1873&#x02013;1885 (2014). Aug 15.<pub-id pub-id-type="pmid">25015828</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Stacey</surname><given-names>AR</given-names></name><etal/></person-group><article-title>Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections</article-title><source>J. Virol.</source><year>2009</year><volume>83</volume><fpage>3719</fpage><lpage>3733</lpage><pub-id pub-id-type="doi">10.1128/JVI.01844-08</pub-id><pub-id pub-id-type="pmid">19176632</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Stacey, A. R. et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. <italic>J. Virol.</italic><bold>83</bold>, 3719&#x02013;3733 (2009).<pub-id pub-id-type="pmid">19176632</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Roff</surname><given-names>SR</given-names></name><name><surname>Noon-Song</surname><given-names>EN</given-names></name><name><surname>Yamamoto</surname><given-names>JK</given-names></name></person-group><article-title>The Significance of Interferon-&#x003b3; in HIV-1 pathogenesis, therapy, and prophylaxis</article-title><source>Front. Immunol.</source><year>2014</year><volume>4</volume><fpage>498</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2013.00498</pub-id><pub-id pub-id-type="pmid">24454311</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Roff, S. R., Noon-Song, E. N. &#x00026; Yamamoto, J. K. The Significance of Interferon-&#x003b3; in HIV-1 pathogenesis, therapy, and prophylaxis. <italic>Front. Immunol.</italic><bold>4</bold>, 498 (2014).<pub-id pub-id-type="pmid">24454311</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>J</given-names></name><etal/></person-group><article-title>Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8+ T cells in primary HIV-1 infection</article-title><source>J. Virol.</source><year>2003</year><volume>77</volume><fpage>6867</fpage><lpage>6878</lpage><pub-id pub-id-type="doi">10.1128/JVI.77.12.6867-6878.2003</pub-id><pub-id pub-id-type="pmid">12768006</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Cao, J. et al. Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8+ T cells in primary HIV-1 infection. <italic>J. Virol.</italic><bold>77</bold>, 6867&#x02013;6878 (2003).<pub-id pub-id-type="pmid">12768006</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>D</given-names></name><etal/></person-group><article-title>Sustained high levels of serum interferon-&#x003b3; during HIV-1 infection: a specific trend different from other cytokines</article-title><source>Viral Immunol.</source><year>2010</year><volume>23</volume><fpage>619</fpage><lpage>625</lpage><pub-id pub-id-type="doi">10.1089/vim.2010.0065</pub-id><pub-id pub-id-type="pmid">21142447</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Watanabe, D. et al. Sustained high levels of serum interferon-&#x003b3; during HIV-1 infection: a specific trend different from other cytokines. <italic>Viral Immunol.</italic><bold>23</bold>, 619&#x02013;625 (2010).<pub-id pub-id-type="pmid">21142447</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Gocher</surname><given-names>AM</given-names></name><name><surname>Workman</surname><given-names>CJ</given-names></name><name><surname>Vignali</surname><given-names>DAA</given-names></name></person-group><article-title>Interferon-&#x003b3;: teammate or opponent in the tumour microenvironment?</article-title><source>Nat. Rev. Immunol.</source><year>2022</year><volume>22</volume><fpage>158</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1038/s41577-021-00566-3</pub-id><pub-id pub-id-type="pmid">34155388</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Gocher, A. M., Workman, C. J. &#x00026; Vignali, D. A. A. Interferon-&#x003b3;: teammate or opponent in the tumour microenvironment? <italic>Nat. Rev. Immunol.</italic><bold>22</bold>, 158&#x02013;172 (2022).<pub-id pub-id-type="pmid">34155388</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Mazet</surname><given-names>JM</given-names></name><etal/></person-group><article-title>IFN&#x003b3; signaling in cytotoxic T cells restricts anti-tumor responses by inhibiting the maintenance and diversity of intra-tumoral stem-like T cells</article-title><source>Nat. Commun.</source><year>2023</year><volume>14</volume><fpage>321</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-35948-9</pub-id><pub-id pub-id-type="pmid">36658158</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Mazet, J. M. et al. IFN&#x003b3; signaling in cytotoxic T cells restricts anti-tumor responses by inhibiting the maintenance and diversity of intra-tumoral stem-like T cells. <italic>Nat. Commun.</italic><bold>14</bold>, 321 (2023).<pub-id pub-id-type="pmid">36658158</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>J</given-names></name><etal/></person-group><article-title>Loss of IFN-&#x003b3; pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 Therapy</article-title><source>Cell</source><year>2016</year><volume>167</volume><fpage>397</fpage><lpage>404.e9</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.08.069</pub-id><pub-id pub-id-type="pmid">27667683</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Gao, J. et al. Loss of IFN-&#x003b3; pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 Therapy. <italic>Cell</italic><bold>167</bold>, 397&#x02013;404.e9 (2016).<pub-id pub-id-type="pmid">27667683</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Interferon-&#x003b3; predicts the treatment efficiency of immune checkpoint inhibitors in cancer patients</article-title><source>J. Cancer Res. Clin. Oncol.</source><year>2023</year><volume>149</volume><fpage>3043</fpage><lpage>3050</lpage><pub-id pub-id-type="doi">10.1007/s00432-022-04201-z</pub-id><pub-id pub-id-type="pmid">35852620</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Liu, J. et al. Interferon-&#x003b3; predicts the treatment efficiency of immune checkpoint inhibitors in cancer patients. <italic>J. Cancer Res. Clin. Oncol.</italic><bold>149</bold>, 3043&#x02013;3050 (2023).<pub-id pub-id-type="pmid">35852620</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>IL</given-names></name><name><surname>Bizilj</surname><given-names>K</given-names></name><name><surname>Colman</surname><given-names>PG</given-names></name><name><surname>Tuch</surname><given-names>BE</given-names></name><name><surname>Harrison</surname><given-names>LC</given-names></name></person-group><article-title>Interferon-gamma induces the expression of HLA-A,B,C but not HLA-DR on human pancreatic beta-cells</article-title><source>J. Clin. Endocrinol. Metab.</source><year>1986</year><volume>62</volume><fpage>1101</fpage><lpage>1109</lpage><pub-id pub-id-type="doi">10.1210/jcem-62-6-1101</pub-id><pub-id pub-id-type="pmid">3084532</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Campbell, I. L., Bizilj, K., Colman, P. G., Tuch, B. E. &#x00026; Harrison, L. C. Interferon-gamma induces the expression of HLA-A,B,C but not HLA-DR on human pancreatic beta-cells. <italic>J. Clin. Endocrinol. Metab.</italic><bold>62</bold>, 1101&#x02013;1109 (1986).<pub-id pub-id-type="pmid">3084532</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Respa</surname><given-names>A</given-names></name><etal/></person-group><article-title>Association of IFN-gamma signal transduction defects with impaired HLA class I antigen processing in melanoma cell lines</article-title><source>Clin. Cancer Res. J. Am. Assoc. Cancer Res.</source><year>2011</year><volume>17</volume><fpage>2668</fpage><lpage>2678</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-2114</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Respa, A. et al. Association of IFN-gamma signal transduction defects with impaired HLA class I antigen processing in melanoma cell lines. <italic>Clin. Cancer Res. J. Am. Assoc. Cancer Res.</italic><bold>17</bold>, 2668&#x02013;2678 (2011).</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>G</given-names></name><etal/></person-group><article-title>IFN-&#x003b3; down-regulates the PD-1 expression and assist nivolumab in PD-1-blockade effect on CD8+ T-lymphocytes in pancreatic cancer</article-title><source>BMC Cancer</source><year>2019</year><volume>19</volume><fpage>1053</fpage><pub-id pub-id-type="doi">10.1186/s12885-019-6145-8</pub-id><pub-id pub-id-type="pmid">31694582</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Ding, G. et al. IFN-&#x003b3; down-regulates the PD-1 expression and assist nivolumab in PD-1-blockade effect on CD8+ T-lymphocytes in pancreatic cancer. <italic>BMC Cancer</italic><bold>19</bold>, 1053 (2019).<pub-id pub-id-type="pmid">31694582</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Scala</surname><given-names>E</given-names></name><etal/></person-group><article-title>Lymphocyte activation gene-3 (LAG-3) expression and IFN-gamma production are variably coregulated in different human T lymphocyte subpopulations</article-title><source>J. Immunol.</source><year>1998</year><volume>161</volume><fpage>489</fpage><lpage>493</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.161.1.489</pub-id><pub-id pub-id-type="pmid">9647260</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Scala, E. et al. Lymphocyte activation gene-3 (LAG-3) expression and IFN-gamma production are variably coregulated in different human T lymphocyte subpopulations. <italic>J. Immunol.</italic><bold>161</bold>, 489&#x02013;493 (1998).<pub-id pub-id-type="pmid">9647260</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Jorgovanovic</surname><given-names>D</given-names></name><name><surname>Song</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><article-title>Roles of IFN-&#x003b3; in tumor progression and regression: a review</article-title><source>Biomark. Res.</source><year>2020</year><volume>8</volume><fpage>49</fpage><pub-id pub-id-type="doi">10.1186/s40364-020-00228-x</pub-id><pub-id pub-id-type="pmid">33005420</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Jorgovanovic, D., Song, M., Wang, L. &#x00026; Zhang, Y. Roles of IFN-&#x003b3; in tumor progression and regression: a review. <italic>Biomark. Res.</italic><bold>8</bold>, 49 (2020).<pub-id pub-id-type="pmid">33005420</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Ni</surname><given-names>L</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name></person-group><article-title>Interferon gamma in cancer immunotherapy</article-title><source>Cancer Med.</source><year>2018</year><volume>7</volume><fpage>4509</fpage><lpage>4516</lpage><pub-id pub-id-type="doi">10.1002/cam4.1700</pub-id><pub-id pub-id-type="pmid">30039553</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Ni, L. &#x00026; Lu, J. Interferon gamma in cancer immunotherapy. <italic>Cancer Med.</italic><bold>7</bold>, 4509&#x02013;4516 (2018).<pub-id pub-id-type="pmid">30039553</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Suh</surname><given-names>WK</given-names></name><etal/></person-group><article-title>The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses</article-title><source>Nat. Immunol.</source><year>2003</year><volume>4</volume><fpage>899</fpage><lpage>906</lpage><pub-id pub-id-type="doi">10.1038/ni967</pub-id><pub-id pub-id-type="pmid">12925852</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">Suh, W. K. et al. The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. <italic>Nat. Immunol.</italic><bold>4</bold>, 899&#x02013;906 (2003).<pub-id pub-id-type="pmid">12925852</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>HY</given-names></name><etal/></person-group><article-title>Transgenic B7-H3 therapy induces tumor-specific immune response in human oral squamous cell cancer: an in vitro study</article-title><source>Oral. Surg. Oral. Med Oral. Pathol. Oral. Radio. Endod.</source><year>2008</year><volume>106</volume><fpage>721</fpage><lpage>728</lpage><pub-id pub-id-type="doi">10.1016/j.tripleo.2008.08.012</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Yang, H. Y. et al. Transgenic B7-H3 therapy induces tumor-specific immune response in human oral squamous cell cancer: an in vitro study. <italic>Oral. Surg. Oral. Med Oral. Pathol. Oral. Radio. Endod.</italic><bold>106</bold>, 721&#x02013;728 (2008).</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>mTORC1 upregulates B7-H3/CD276 to inhibit antitumor T cells and drive tumor immune evasion</article-title><source>Nat. Commun.</source><year>2023</year><volume>14</volume><fpage>1214</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-36881-7</pub-id><pub-id pub-id-type="pmid">36869048</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Liu, H. J. et al. mTORC1 upregulates B7-H3/CD276 to inhibit antitumor T cells and drive tumor immune evasion. <italic>Nat. Commun.</italic><bold>14</bold>, 1214 (2023).<pub-id pub-id-type="pmid">36869048</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>C</given-names></name><etal/></person-group><article-title>Frequent B7-H3 overexpression in craniopharyngioma</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2019</year><volume>514</volume><fpage>379</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2019.04.142</pub-id><pub-id pub-id-type="pmid">31043272</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Chen, C. et al. Frequent B7-H3 overexpression in craniopharyngioma. <italic>Biochem. Biophys. Res. Commun.</italic><bold>514</bold>, 379&#x02013;385 (2019).<pub-id pub-id-type="pmid">31043272</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>M</given-names></name><etal/></person-group><article-title>Altered spatial composition of the immune cell repertoire in association to CD34+ blasts in myelodysplastic syndromes and secondary acute myeloid leukemia</article-title><source>Cancers</source><year>2021</year><volume>13</volume><fpage>186</fpage><pub-id pub-id-type="doi">10.3390/cancers13020186</pub-id><pub-id pub-id-type="pmid">33430322</pub-id>
</element-citation><mixed-citation id="mc-CR55" publication-type="journal">Bauer, M. et al. Altered spatial composition of the immune cell repertoire in association to CD34+ blasts in myelodysplastic syndromes and secondary acute myeloid leukemia. <italic>Cancers</italic><bold>13</bold>, 186 (2021).<pub-id pub-id-type="pmid">33430322</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><mixed-citation publication-type="other">Feng, Z. et al. Multiparametric immune profiling in HPV- oral squamous cell cancer. <italic>JCI Insight</italic>. <bold>2</bold>, e93652 (2017).</mixed-citation></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>M</given-names></name><etal/></person-group><article-title>Prognostic impact of the bone marrow tumor microenvironment, HLA-I and HLA-Ib expression in MDS and CMML progression to sAML</article-title><source>OncoImmunology</source><year>2024</year><volume>13</volume><fpage>2323212</fpage><pub-id pub-id-type="doi">10.1080/2162402X.2024.2323212</pub-id><pub-id pub-id-type="pmid">38481730</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Bauer, M. et al. Prognostic impact of the bone marrow tumor microenvironment, HLA-I and HLA-Ib expression in MDS and CMML progression to sAML. <italic>OncoImmunology</italic><bold>13</bold>, 2323212 (2024).<pub-id pub-id-type="pmid">38481730</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Kontos</surname><given-names>F</given-names></name><etal/></person-group><article-title>B7-H3: an attractive target for antibody-based immunotherapy</article-title><source>Clin. Cancer Res. J. Am. Assoc. Cancer Res.</source><year>2021</year><volume>27</volume><fpage>1227</fpage><lpage>1235</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-20-2584</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Kontos, F. et al. B7-H3: an attractive target for antibody-based immunotherapy. <italic>Clin. Cancer Res. J. Am. Assoc. Cancer Res.</italic><bold>27</bold>, 1227&#x02013;1235 (2021).</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>WT</given-names></name><name><surname>Jin</surname><given-names>WL</given-names></name></person-group><article-title>B7-H3/CD276: an emerging cancer immunotherapy</article-title><source>Front. Immunol.</source><year>2021</year><volume>12</volume><fpage>701006</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2021.701006</pub-id><pub-id pub-id-type="pmid">34349762</pub-id>
</element-citation><mixed-citation id="mc-CR59" publication-type="journal">Zhou, W. T. &#x00026; Jin, W. L. B7-H3/CD276: an emerging cancer immunotherapy. <italic>Front. Immunol.</italic><bold>12</bold>, 701006 (2021).<pub-id pub-id-type="pmid">34349762</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Feustel</surname><given-names>K</given-names></name><name><surname>Martin</surname><given-names>J</given-names></name><name><surname>Falchook</surname><given-names>GS</given-names></name></person-group><article-title>B7-H3 inhibitors in oncology clinical trials: a review</article-title><source>J. Immunother. Precis Oncol.</source><year>2024</year><volume>7</volume><fpage>53</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.36401/JIPO-23-18</pub-id><pub-id pub-id-type="pmid">38327753</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">Feustel, K., Martin, J. &#x00026; Falchook, G. S. B7-H3 inhibitors in oncology clinical trials: a review. <italic>J. Immunother. Precis Oncol.</italic><bold>7</bold>, 53&#x02013;66 (2024).<pub-id pub-id-type="pmid">38327753</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>Aggarwal</surname><given-names>C</given-names></name><etal/></person-group><article-title>Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial</article-title><source>J. Immunother. Cancer</source><year>2022</year><volume>10</volume><fpage>e004424</fpage><pub-id pub-id-type="doi">10.1136/jitc-2021-004424</pub-id><pub-id pub-id-type="pmid">35414591</pub-id>
</element-citation><mixed-citation id="mc-CR61" publication-type="journal">Aggarwal, C. et al. Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial. <italic>J. Immunother. Cancer</italic><bold>10</bold>, e004424 (2022).<pub-id pub-id-type="pmid">35414591</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Q</given-names></name><etal/></person-group><article-title>B7-H3 targeted CAR-T cells show highly efficient anti-tumor function against osteosarcoma both in vitro and in vivo</article-title><source>BMC Cancer</source><year>2022</year><volume>22</volume><fpage>1124</fpage><pub-id pub-id-type="doi">10.1186/s12885-022-10229-8</pub-id><pub-id pub-id-type="pmid">36320072</pub-id>
</element-citation><mixed-citation id="mc-CR62" publication-type="journal">Zhang, Q. et al. B7-H3 targeted CAR-T cells show highly efficient anti-tumor function against osteosarcoma both in vitro and in vivo. <italic>BMC Cancer</italic><bold>22</bold>, 1124 (2022).<pub-id pub-id-type="pmid">36320072</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name><surname>Trickey</surname><given-names>A</given-names></name><etal/></person-group><article-title>Longitudinal trends in causes of death among adults with HIV on antiretroviral therapy in Europe and North America from 1996 to 2020: a collaboration of cohort studies</article-title><source>Lancet Hiv.</source><year>2024</year><volume>11</volume><fpage>e176</fpage><lpage>e185</lpage><pub-id pub-id-type="doi">10.1016/S2352-3018(23)00272-2</pub-id><pub-id pub-id-type="pmid">38280393</pub-id>
</element-citation><mixed-citation id="mc-CR63" publication-type="journal">Trickey, A. et al. Longitudinal trends in causes of death among adults with HIV on antiretroviral therapy in Europe and North America from 1996 to 2020: a collaboration of cohort studies. <italic>Lancet Hiv.</italic><bold>11</bold>, e176&#x02013;e185 (2024).<pub-id pub-id-type="pmid">38280393</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>RL</given-names></name><name><surname>de Boer</surname><given-names>R</given-names></name><name><surname>Brul</surname><given-names>S</given-names></name><name><surname>Budovskaya</surname><given-names>Y</given-names></name><name><surname>van Spek</surname><given-names>H</given-names></name></person-group><article-title>Premature and accelerated aging: HIV or HAART?</article-title><source>Front. Genet.</source><year>2012</year><volume>3</volume><fpage>328</fpage><pub-id pub-id-type="pmid">23372574</pub-id>
</element-citation><mixed-citation id="mc-CR64" publication-type="journal">Smith, R. L., de Boer, R., Brul, S., Budovskaya, Y. &#x00026; van Spek, H. Premature and accelerated aging: HIV or HAART? <italic>Front. Genet.</italic><bold>3</bold>, 328 (2012).<pub-id pub-id-type="pmid">23372574</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name><surname>Carr</surname><given-names>A</given-names></name></person-group><article-title>Toxicity of antiretroviral therapy and implications for drug development</article-title><source>Nat. Rev. Drug Discov.</source><year>2003</year><volume>2</volume><fpage>624</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1038/nrd1151</pub-id><pub-id pub-id-type="pmid">12904812</pub-id>
</element-citation><mixed-citation id="mc-CR65" publication-type="journal">Carr, A. Toxicity of antiretroviral therapy and implications for drug development. <italic>Nat. Rev. Drug Discov.</italic><bold>2</bold>, 624&#x02013;634 (2003).<pub-id pub-id-type="pmid">12904812</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name><surname>Spengler</surname><given-names>U</given-names></name><name><surname>Lichterfeld</surname><given-names>M</given-names></name><name><surname>Rockstroh</surname><given-names>JK</given-names></name></person-group><article-title>Antiretroviral drug toxicity - a challenge for the hepatologist?</article-title><source>J. Hepatol.</source><year>2002</year><volume>36</volume><fpage>283</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1016/S0168-8278(01)00311-7</pub-id><pub-id pub-id-type="pmid">11830343</pub-id>
</element-citation><mixed-citation id="mc-CR66" publication-type="journal">Spengler, U., Lichterfeld, M. &#x00026; Rockstroh, J. K. Antiretroviral drug toxicity - a challenge for the hepatologist? <italic>J. Hepatol.</italic><bold>36</bold>, 283&#x02013;294 (2002).<pub-id pub-id-type="pmid">11830343</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name><surname>Cubasch</surname><given-names>H</given-names></name><etal/></person-group><article-title>South African breast cancer and hiv outcomes study: methods and baseline assessment</article-title><source>J. Glob. Oncol.</source><year>2017</year><volume>3</volume><fpage>114</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1200/JGO.2015.002675</pub-id><pub-id pub-id-type="pmid">28706996</pub-id>
</element-citation><mixed-citation id="mc-CR67" publication-type="journal">Cubasch, H. et al. South African breast cancer and hiv outcomes study: methods and baseline assessment. <italic>J. Glob. Oncol.</italic><bold>3</bold>, 114&#x02013;124 (2017).<pub-id pub-id-type="pmid">28706996</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name><surname>McKenzie</surname><given-names>F</given-names></name><etal/></person-group><article-title>African Breast Cancer-Disparities in Outcomes (ABC-DO): protocol of a multicountry mobile health prospective study of breast cancer survival in sub-Saharan Africa</article-title><source>BMJ Open.</source><year>2016</year><volume>6</volume><fpage>e011390</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2016-011390</pub-id><pub-id pub-id-type="pmid">27554102</pub-id>
</element-citation><mixed-citation id="mc-CR68" publication-type="journal">McKenzie, F. et al. African Breast Cancer-Disparities in Outcomes (ABC-DO): protocol of a multicountry mobile health prospective study of breast cancer survival in sub-Saharan Africa. <italic>BMJ Open.</italic><bold>6</bold>, e011390 (2016).<pub-id pub-id-type="pmid">27554102</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><mixed-citation publication-type="other">WHO Classification of Tumours Editorial Board. Breast tumours. WHO Classification of Tumours. 5th ed. Vol. 2 (OMS, Geneva, 2019).</mixed-citation></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name><surname>Pinder</surname><given-names>SE</given-names></name><etal/></person-group><article-title>The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy</article-title><source>Cancer</source><year>1998</year><volume>83</volume><fpage>1529</fpage><lpage>1539</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0142(19981015)83:8&#x0003c;1529::AID-CNCR7&#x0003e;3.0.CO;2-V</pub-id><pub-id pub-id-type="pmid">9781946</pub-id>
</element-citation><mixed-citation id="mc-CR70" publication-type="journal">Pinder, S. E. et al. The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy. <italic>Cancer</italic><bold>83</bold>, 1529&#x02013;1539 (1998).<pub-id pub-id-type="pmid">9781946</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name><surname>Goldhirsch</surname><given-names>A</given-names></name><etal/></person-group><article-title>Strategies for subtypes&#x02014;dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2011</article-title><source>Ann. Oncol.</source><year>2011</year><volume>22</volume><fpage>1736</fpage><lpage>1747</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdr304</pub-id><pub-id pub-id-type="pmid">21709140</pub-id>
</element-citation><mixed-citation id="mc-CR71" publication-type="journal">Goldhirsch, A. et al. Strategies for subtypes&#x02014;dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2011. <italic>Ann. Oncol.</italic><bold>22</bold>, 1736&#x02013;1747 (2011).<pub-id pub-id-type="pmid">21709140</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name><surname>Allison</surname><given-names>KH</given-names></name><etal/></person-group><article-title>Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP Guideline Update</article-title><source>J. Clin. Oncol.</source><year>2020</year><volume>38</volume><fpage>1346</fpage><lpage>1366</lpage><pub-id pub-id-type="doi">10.1200/JCO.19.02309</pub-id><pub-id pub-id-type="pmid">31928404</pub-id>
</element-citation><mixed-citation id="mc-CR72" publication-type="journal">Allison, K. H. et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP Guideline Update. <italic>J. Clin. Oncol.</italic><bold>38</bold>, 1346&#x02013;1366 (2020).<pub-id pub-id-type="pmid">31928404</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name><surname>Wolff</surname><given-names>AC</given-names></name><etal/></person-group><article-title>Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update</article-title><source>J. Clin. Oncol.</source><year>2023</year><volume>41</volume><fpage>3867</fpage><lpage>3872</lpage><pub-id pub-id-type="doi">10.1200/JCO.22.02864</pub-id><pub-id pub-id-type="pmid">37284804</pub-id>
</element-citation><mixed-citation id="mc-CR73" publication-type="journal">Wolff, A. C. et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update. <italic>J. Clin. Oncol.</italic><bold>41</bold>, 3867&#x02013;3872 (2023).<pub-id pub-id-type="pmid">37284804</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name><surname>Sch&#x000fc;mann</surname><given-names>FL</given-names></name><etal/></person-group><article-title>Divergent effects of EZH1 and EZH2 protein expression on the prognosis of patients with T-Cell lymphomas</article-title><source>Biomedicines</source><year>2021</year><volume>9</volume><fpage>1842</fpage><pub-id pub-id-type="doi">10.3390/biomedicines9121842</pub-id><pub-id pub-id-type="pmid">34944658</pub-id>
</element-citation><mixed-citation id="mc-CR74" publication-type="journal">Sch&#x000fc;mann, F. L. et al. Divergent effects of EZH1 and EZH2 protein expression on the prognosis of patients with T-Cell lymphomas. <italic>Biomedicines</italic><bold>9</bold>, 1842 (2021).<pub-id pub-id-type="pmid">34944658</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>M</given-names></name><etal/></person-group><article-title>Multiplex immunohistochemistry as a novel tool for the topographic assessment of the bone marrow stem cell niche</article-title><source>Methods Enzymol.</source><year>2020</year><volume>635</volume><fpage>67</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1016/bs.mie.2019.05.055</pub-id><pub-id pub-id-type="pmid">32122554</pub-id>
</element-citation><mixed-citation id="mc-CR75" publication-type="journal">Bauer, M. et al. Multiplex immunohistochemistry as a novel tool for the topographic assessment of the bone marrow stem cell niche. <italic>Methods Enzymol.</italic><bold>635</bold>, 67&#x02013;79 (2020).<pub-id pub-id-type="pmid">32122554</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Anders</surname><given-names>S</given-names></name></person-group><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biol.</source><year>2014</year><volume>15</volume><fpage>550</fpage><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id>
</element-citation><mixed-citation id="mc-CR76" publication-type="journal">Love, M. I., Huber, W. &#x00026; Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. <italic>Genome Biol.</italic><bold>15</bold>, 550 (2014).<pub-id pub-id-type="pmid">25516281</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>